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Chronic kidney disease (CKD) is a global disease affecting 10% of the world 
population and is largely treated by dialysis and organ transplant at late stages of 
disease. As rates of CKD rise, it is increasingly evident that novel drug targets are 
required for intervention before these late stages are reached. The purinergic receptor 
sub-type 7 (P2X7) may represent such a drug target. P2X7, an ATP-gated ion channel, 
is part of the purinergic signalling pathway and antagonists are safe and well-tolerated 
in clinical trials as a treatment for inflammatory disease. These trials did not show 
therapeutic benefit, but recent findings suggest that vascular, rather than immune, 
functions of P2X7 may be important for renal disease. This project aimed to investigate 
the expression and role of P2X7 in the renal vasculature in both normal and 
hypertensive mice. A mouse model of multi-hit renal vascular injury was established 
and characterised through the administration of angiotensin II (ANGII), 
deoxycorticosterone (DOCA) and a high salt diet (ANGII DOCA salt model). ANGII 
DOCA salt mice exhibited mild hypertension, moderate albuminuria, vascular 
dysfunction, perivascular fibrosis, and a marked increase in renal injury markers in 
both whole kidney and urine, compared to sham-operated (Sham) littermates. A 
systematic immunofluorescence study localised P2X7 to the endothelium of renal 
vessels and glomerular capillaries in both Sham and ANGII DOCA salt mice, as well 
as localising to areas of injury in ANGII DOCA salt mouse kidneys. The P2X7 
antagonist A438079 was able to inhibit ATP-stimulated release of IL-1B in LPS-
primed mouse macrophages and was therefore used to assess vascular function in 
isolated aorta by wire myography. These studies found that activation of P2X7 via 
agonist BzATP led to vasoconstriction in both mouse groups, an effect that was 
amplified upon P2X7 inhibitions. Following these findings, it is possible that this is 
due to a shift in the expression of different P2X7 isoforms with potentially opposing 
vasoactivity in ANGII DOCA salt mice, compared to Sham mice. This is supported by 
the observation of differential expression of P2X7 according to the tissue used, the 
method of detection used, and the disease model investigated. This thesis highlights 
the importance of considering splice variation under normo- and pathophysiological 


























Chronic kidney disease (CKD) is a global disease affecting more than 10% of the 
world population. It is an illness that establishes itself over the course of many years, 
eventually leading to kidney failure, which requires treatment through dialysis and 
organ transplant. These treatments are difficult and costly, and so current research 
focuses on identifying drugs that can be used to combat CKD early on in its 
progression. One potential drug is a blocker of P2X7. P2X7 is a protein found on cells 
in renal blood vessels that binds energy molecules called ATP, that circulate in our 
blood. It has been observed that, in both humans and rodents with kidney disease, 
levels of P2X7 are increased and that blocking P2X7 may improve the symptoms of 
kidney disease, through lowering blood pressure and restoring blood flow to the 
kidney. However, little is known about the function of P2X7 in this area. To investigate 
this, we observed P2X7 in both healthy mice and mice with kidney disease. We saw 
that, although P2X7 was seen in similar places in the kidneys of both groups of mice, 
it appeared to be present at areas of injury in the kidneys of mice with renal disease at 
much higher levels. When we investigated the activity of P2X7 in these mice, we saw 
that activating P2X7 caused blood vessels to tighten i.e. vasoconstrict. We therefore 
hypothesised that blocking P2X7 would cause vessels to widen i.e. vasodilation. 
However, this was not the case. It is possible that this is because there are many 
different types of P2X7 in our bodies, called isoforms. These isoforms are encoded 
into our genes and are a natural part of human evolution. However, different P2X7 
isoforms may have different functions in different parts of our bodies. We have seen 
some differences in P2X7 isoform expression and location in healthy mouse and 
diseased mouse kidneys. The work presented here highlights the importance of P2X7 
































ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
ANG II Angiotensin II 
ANOVA Analysis of variance 
ARG Arginase 
ATP Adenosine 5'-triphosphate 
AU Arbitrary 
BHT Butylated hydroxytoluene 
BMDM Bone marrow derived macrophages 
BMP Bone morphogenic protein 
BP Blood pressure 
BV Blue-Violet 
BW Body weight 
BzATP 3'-0-(4-Benzoyl)benzoyl ATPATP triethylammonium salt  
°C Degrees Celsius 
Ca Calcium 
CaCl2 Calcium chloride 
CCD Cortical collecting duct 
CD31 Cluster of differentiation 31 
CD68 Cluster of differentiation 68 
cDNA Complimentary DNA 
CI Confidence intervals 
CKD Chronic Kidney Disease 
CO2 Carbon dioxide 
COL Collagen 
CY7 Cyanine 7 
Da Dalton 
DAPI 4′,6-diamidino-2-phenylindole 
ddH2O Double distilled water 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
DOCA Deoxycorticosterone 
EC50 Half maximal effective concentration 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
eGFR Estimated GFR 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial-mesenchymal transition 
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eRPF Estimated RPF 
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FACS Fluorescence-activated cell sorting 
FDA Food and drug administration 
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HIER Heat-induced epitope retrieval 
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IRI Ischaemic reperfusion injury 
K Potassium 
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kg kilograms 
K2HPO4 Dipotassium phosphate 
KIM Kidney injury molecule 
KO Knock out 
KPSS High potassium physiological salt 
L Litres 
LPS Lipopolysaccharide 
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M Molarity 
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NO Nitric oxide 
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p Probability value 
P1R Purinergic 1 receptors 
P2R Purinergic 2 receptors 
P2X Purinergic 2 X receptor 
P2X7 Purinergic 2 X receptor 7 
P2X7(e)  Purinergic 2 X receptor 7 intracellular targeting antibody 
P2X7(i) Purinergic 2 X receptor 7 extracellular targeting antibody 
P2X713B Purinergic 2 X receptor 7 variant 13B 
P2X713C Purinergic 2 X receptor 7 variant 13C 
P2X7k Purinergic 2 X receptor 7 variant k 
p2xr7 Gene encoding P2X7 
p2xr7-/- P2X7 knock out 
P2Xx Purinergic 2 X receptor x 
P2Y Purinergic 2 Y Receptor 
PAH para-aminohippuric acid 
PCR Polymerase chain reaction 
PDGFR Platelet derived growth factor receptor 
PE Phenylephrine 
PECAM Platelet-endothelial cell adhesion molecule 
PFA Paraformaldehyde 
PN Pressure natriuresis 
PSS Physiological salt solution 
qPCR quantitative PCR 
RAAS Renin angiotensin aldosterone system 
RBF Renal blood flow 
RNA Ribonucleic acid 
RPF Renal plasma flow 
RVR Renal vascular resistance 
S.D Standard deviation 
S.E.M Standard error of the mean 
SBP Systolic blood pressure 
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SMA Smooth muscle actin 
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TGF Transforming growth factor 
TIM T-cell immunoglobulin and mucin domain 
TNF Tumour necrosis factor 
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UTP Uridine triphosphate 
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1.1 Chronic Kidney Disease 
 
1.1.1 Overview of Chronic Kidney Disease 
Chronic kidney disease (CKD) is a global disease affecting 10% of the world’s 
population and its patients are one of the most ‘at-risk’ groups for the progression of 
cardiovascular conditions (Eckardt et al. 2013; Gansevoort et al. 2013). CKD 
represents a complex condition, with many contributors to its progression, including 
hypoxia, inflammation, vascular dysfunction and hypertension (Nakayama et al. 
2011). Despite high socio-economic burden and widespread prevalence, treatment 
options for CKD are limited and hypertension remains a major modifiable risk factor 
for the disease. There is therefore an unmet need to identify new druggable targets to 
expand CKD treatment options (Remuzzi et al. 2013).   
1.1.2 CKD: a cycle of injury and fibrosis 
An extensive literature places sustained tubulointerstitial inflammation at the heart of 
CKD. Such inflammation primes the kidney for a cycle of injury and fibrosis and can 
impair the acute pressure natriuresis response (PN), the physiological processes 
through which the kidney regulates long-term blood pressure (Franco et al. 2013). 
Under normal circumstances, an increase in blood pressure (BP) leads to increased 
renal arterial perfusion, which stimulates the kidney to excrete sodium, reducing 
extracellular fluid volume and intravascular vascular volume and hence normalizing 
BP. If the PN response becomes impaired, long term BP control is lost and barotrauma 
of the renal microvasculature can provoke a further cycle of injury and inflammation, 
ultimately leading to fibrosis and a decline in renal function (Ivy & Bailey 2014).  
This cycle can be broken down into stages of pathophysiology, which overlap and 
influence each other as disease progresses. Microvasculature damage and thus, 
hypoxia and endothelial dysfunction can lead to vasoconstriction and reduced blood 
flow in the kidney, leading to release of HIFs (hypoxia-induced factors) and loss of 




Upon induction of interstitial inflammation and recruitment of macrophages, 
neutrophils, T-cells and B-cells, ILs (interleukins) and damage-associated molecular 
patterns (DAMPs) are activated and released, further amplifying the immune response. 
As the damage continues, reparatory cells such as inflammatory cells and newly 
activated myofibroblasts contribute to a build-up of collagen in order to alleviate 
cellular injury. Matrix deposition increases and fibrosis occurs, first at interstitial, 
glomerular and perivascular areas, and later at tubular epithelial cells, resulting in 
further dysregulation, damage and injury. (For comprehensive reviews of these 
processes, please see Romagnani et al. 2017 & Guzzi et al. 2019) 
As is evident, there are many layers and potential points of entry into the cycle of CKD. 
Historically, pharmacological treatment of CKD has focussed on targeting fibrosis. 
This, and other treatment potentials, are discussed below. 
1.2 Treatment of CKD 
1.2.1 Targeting fibrosis as a CKD treatment option 
Fibrosis is an essential part of tissue repair, acting as a short term ‘wound healing’ 
response to injury. However, in chronic injury, when fibrosis is maintained over a long 
period of time, it can prevent the organ affected from functioning properly. This is true 
of the kidneys, where extensive fibrosis is a common end point of CKD (Rockey et al. 
2015). Fibrosis is often the focus of CKD therapeutics, as it isn’t until fibrosis is 
established and resultant changes in renal function translate to symptoms and thus 
patient presentation, that CKD is treated. However, the process of cross linking of 
extracellular matrix that occurs during fibrosis, makes it difficult to reverse. In the 
kidney, reversal of fibrosis and resulting damage to tubules is a difficult and lengthy 
process. Studies have found that reversal of renal fibrosis in rodents is possible, for 
example through administration of bone morphogenic protein (BMP-7) following 
transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition 
(EMT). EMT is a biological process that occurs in which epithelial cells transition into 
the mesenchymal cells that participate in tissue repair and the pathological process of 
fibrosis) (Zeisberg et al. 2003). In this paper, reversal of fibrosis was observed after 
treatment – however, the rodent model used captured only one aspect of fibrosis 
(EMT) and the treatment was given from 1 week after injury induction, a full 3 weeks 
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before end stages of CKD were reached. The observation that many studies often give 
treatment at these time scales, or even prophylactic treatment, is difficult to align with 
human pathology, where treatment occurs at end stages of disease. As such, no clinical 
studies have yet provided evidence for fibrosis reversal in humans (Zeisberg & 
Zeisberg 2015). The complex signalling pathways involved in fibrosis across many 
different cell types makes fibrosis difficult to treat and many studies aiming to target 
such pathways in the treatment of CKD have been unsuccessful (Boor et al. 2007). At 
present, early stage biomarkers of renal disease are sparse; currently, kidney injury 
molecule-1 (KIM-1) is the only FDA approved renal injury biomarker. Emerging 
research into biomarkers could make identification of early kidney injury more and 
more plausible, as treatment at preclinical stages of CKD is becoming more and more 
appealing (Tampe & Zeisberg 2014).  
Under these circumstances, injury can be halted early on, before fibrosis even sets in, 
entirely avoiding any associated decline in renal function. The exact origins and 
starting point of CKD is often debated, making its diagnosis difficult. Current NICE 
guidelines advise creatinine-based estimation of glomerular filtration rate (eGFR) as 
the first point of call for diagnosis of CKD, along with albuminuria tests 
(https://www.nice.org.uk/guidance/cg182). However, this method carries limitations, 
such as variability in results and low sensitivity in certain subjects. Research efforts 
are therefore currently focussing on identifying biomarkers at early stages of CKD. 
Characterising and understanding early stages of CKD at the molecular and 
physiological level is vital in identifying novel drug targets and markers at this phase. 
1.2.2 Targeting the vasculature as a CKD treatment option 
In 1998, it was proposed that vascular dysfunction was a common early hallmark of 
CKD and more than this, sustained vascular abnormalities played a causal role in the 
progression to renal disease (Fine et al. 1998). This hypothesis, proposed by Fine and 
colleagues, suggested that primary glomerular diseases, such as hypertension, leads to 
changes in the microvasculature which compromise renal blood supply, generating a 
local hypoxic environment at the tubule-interstitium. Hypoxia encourages production 
of hypoxia inducible factor (HIF)-1α, which acts as a transcription factor for a 
multitude of pro-fibrotic factors that act to build the extracellular matrix (ECM), 
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induce fibrosis and promote further loss of vasculature and decline of renal blood flow 
(Norman & Fine 2006). Thus, the ‘chronic hypoxia hypothesis’ posits that renal 
microvascular dysfunction and/or rarefaction creates a hostile, pro-inflammatory 
environment in the renal medulla and locks the kidney in a cycle of declining renal 
function (Fine et al. 1998).  
Whether or not this cycle of progressive renal disease has a single point of entry is not 
established but it is likely that interstitial inflammation is also an important early event 
underlying vascular dysfunction (Rodríguez-Iturbe et al. 2014; Johnson et al. 2005). 
Anti-inflammatory strategies can restore the acute PN response and improve blood 
pressure control in hypertensive rodents (Franco et al. 2013; Ji et al. 2012a; Ji et al. 
2012b). Treatment of early vascular dysfunction and inflammation may therefore be 
much more effective than an attempt to treat end stage symptoms of CKD, such as 
fibrosis. Pharmaceutical companies are currently turning to these time points; 
identification of drug targets active within this time period may be crucial in the 
treatment of early stage CKD, and prevent later stages, of CKD. 
 
Figure 1.1 - The pathophysiological processes linked to kidney disease. Schematics 
of (A) a normal, healthy kidney and (B) a kidney with chronic injury, exhibiting 




1.3 Models of CKD 
 
To explore treatment options for CKD, a range of rodent models are characterised, 
primarily in the rat and the mouse. Many of these models apply focus on fibrosis, and 
some have a vascular focus; these are discussed below. 
One model that uses genetic intervention is the mRen2 rat. This model exhibits 
hypertension and characteristics of a dysfunctional renin aldosterone angiotensin 
system (RAAS) and abnormal renal vascular tone, such as increased angiotensin II 
(ANGII) production, vasoconstriction and upregulated sodium reabsorption. Fibrosis 
in this model is rapid and intense, reaching end organ damage by 8 weeks (Mullins et 
al. 2016). This captures many of fibrotic and vascular elements common at late stages 
of CKD, however does not realistically capture the timeline of human CKD, which 
takes years to progress.  
A surgical model of rapid fibrosis, commonly used in both rats and mice is the 
unilateral ureteral obstruction (UUO) model, which demonstrates phenotypes of 
interstitial inflammation, tubular dilation and atrophy, alongside fibrosis and a drop in 
renal blood flow (RBF) and glomerular filtration rate (GFR)(Yang et al. 2010; Mullins 
et al. 2016). This model also progresses rapidly, again missing the slow progression of 
human CKD. 
Renal injury can also be induced through renal mass reduction, such as through the 5/6 
nephrectomy model, with added ischaemic reperfusion injury (IRI) (Mullins et al. 
2016). Vascular phenotypes are also observed in this model alongside progressive 
fibrosis, such as capillary rarefaction and downregulation of vascular endothelial 
growth factor (VEGF), which is required for growth of new blood vessels. Because of 
the progressive nature of this model, as well as the establishment of vascular and 
fibrotic phenotypes, it’s an interesting model to study in the context of CKD, however 
the surgery is complex and carries a high mortality rate, making it difficult to access 
(Mullins et al. 2016). 
Components of CKD can also be induced through pharmacological intervention; 
nephrotoxic nephritis (NTN) can be achieved through administration of anti-
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glomerular immunoglobulins (IgG). This results in glomerular nephritis, which is to 
be expected, alongside proteinuria and histological changes in the kidney that mimic 
human disease (Mullins et al., 2016). This model does, however, only capture some 
elements of CKD, and exhibits high rate of disease variation between animal cohorts, 
making it difficult to obtain reproducible data with reliable conclusions. 
Deoxycortisone acetate and a high salt diet (DOCA-salt) can also be used in 
conjunction with a unilateral nephrectomy to induce hypertension and renal injury in 
rodents, particularly in C57BL/6 mice which are quite resistant to renal injury. 
Interestingly, the vascular elements of CKD are well captured in this model, with 
impaired endothelial-dependant relaxation observed as well as increased extracellular 
matrix deposition (Yang et al. 2010). However, this is again a rapidly progressing 
model, with severe hypertension observed within a few weeks. 
These are just a few examples of models currently used to explore CKD. They capture 
different elements of the disease; vascular, inflammatory, fibrotic, and each has its 
uses and limitation. Reviewing these models shows there is a wide range of potential 
mediators for the establishment of CKD. In many of the models described above, 
function and/or expression of purinergic signalling is disrupted, representing one 













1.4 Purinergic Signalling 
1.4.1 Overview of Purinergic Signalling 
Two categories of purinergic receptor are defined; P1, which bind adenosine and P2, 
which can be activated by purine or pyrimidine nucleotides. This binding leads to an 
array of cellular responses, often in the form of an increase in cellular calcium ions 
(Booth et al. 2012).  
Figure 1.2 – An overview of purinergic signalling. In extracellular spaces, ATP can 
be broken down into a sequence of products, ADP, 5’AMP and Adenosine. Each of 
these products then binds to a different type of purinergic receptor to mediate a range 
of downstream cellular responses. Source: (Booth et al. 2012). 
P2R are further subdivided: P2Y are G-protein coupled receptors and the 7 subtypes 
have differential selectivity for ATP, ADP, UTP and UDP; P2XR are ligand-gated ion 
channels (IUPHAR database: http://www.iuphar-db.org/) activated by ATP. Most P2R 
subtypes are expressed in the kidney and purinergic signalling exerts marked 
physiological effects on renal blood flow and epithelial transport properties, as 
reviewed in detail (Shirley et al. 2013; Burnstock et al. 2014). 
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1.4.2 The role of purinergic receptors in renal disease 
Targeting the purinergic receptor family is one current avenue for the treatment of 
renal disease. 
It is increasingly recognised that ATP signalling via P2R contributes to a variety of 
pathophysiological conditions, ranging from hypertension (Menzies et al. 2015), 
transplant rejection and polycystic kidney disease (Solini et al. 2013).  
Purinergic receptors can be found throughout the nephron, and they have been 
identified as playing physiological roles in tubuloglomerular feedback, the 
autoregulatory response of renal vasculature, electrolyte transport and control of renin 
release. Given these widespread locations and roles within the kidney, it’s not 
surprising that purinergic signalling is also associated with the renal 
pathophysiological conditions listed above, as well as nephritis, diabetes and 
nephrotoxicant injury (Burnstock & Ralevic 2014). 
Purinergic receptors are present in both renal vascular tissue and immune cells and the 
role of P2X receptors in both locations has been explored (Lewis & Evans 2001; 
Menzies et al. 2013; North 2002). Increased P2X7 activation in particular is strongly 
associated with kidney disease and elevated expression of these receptors in the 
“normal” state increases the susceptibility to hypertensive renal vascular injury 
(Menzies et al. 2013; Menzies et al. 2017). P2X7 expression is also upregulated in 
rodent models of type 1 diabetes and hypertension, as well as in human and 
experimental glomerulonephritis (Vonend et al. 2004a; Turner et al. 2007; Taylor et 
al. 2009; Menzies et al. 2017). Human studies are more limited but genetic association 
studies in human populations have uncovered significant association between a 
singular P2X7 single nuclear polymorphism and increased blood pressure (Palomino-
Doza et al. 2008). These studies strongly link the dysregulation of P2X7 expression 
with hypertension and renal injury and pose P2X7 as a promising target therapeutic 






1.5 The P2X7 receptor: structure and function 
1.5.1 Overview of P2X7 structure and function 
There is additional complexity in studying P2X receptors, as a number of splice 
variants of P2X7 receptors have also been reported, both in rodents and humans (Masin 
et al. 2012; Cheewatrakoolpong et al. 2005; Nicke et al. 2009). Such splice variants 
have been deemed responsible for a range of altered phenotypes, including varied pain 
responses, differential response to agonists and even mistargeted gene knockout 
(Hansen et al. 2011; Xu et al. 2012; Nicke et al. 2009; Bartlett et al. 2014). P2X7 splice 
variants have also been shown to vary in their interaction with pannexin-1, which, as 
mentioned, plays an important role in the inflammatory action of P2X7 (Xu et al. 2012; 
Pelegrin & Surprenant 2006; Hung et al. 2013).  
  
 
The number of splice variants observed across different species and the functional 
significance they may have in disease is still unclear and must be further investigated 
in order to effectively target any unfavourable action of P2X7.  
Isoform NCBI RefSeq Alt. name Reference Properties GKS KO Pfizer KO
 - fully functional variant
 - 8-fold higher sensitivity to P2X7 
agonists
 - slower deactivation
 - increased propensity to form P2X7 
pores 
 - preferentially expressed by T cells
 - canonical 
 - preferentially expressed by 
macrophages
 - strongest expressin in brain, salivary 
glands, lung
 - low cell surface expression, low 
channel function, no pore formation
 - strongest expressin in brain, salivary 
glands, spleen
 - low cell surface expression, low 
channel function, no pore formation
 - apparently hetero-oligomerizess with 
P2X7 to inhibit it
D NM_001038887.1 - Predicted - - -











Masin et al 2012
Masin et al 2012




Table 1.1 - An overview of the P2X7 splice isoforms in mice, including 
GlaxoSmithKline knock out (GSK KO) and Pfizer knock out (Pfizer KO)  
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1.5.2 P2X7 in inflammation and renal fibrosis 
Enhanced P2X signalling has long been thought to be contributory in chronic 
inflammatory disease. P2X7 is expressed on many immune cells, including 
macrophages and other antigen-presenting cells (Surprenant et al. 1996; Lister et al. 
2007), as well as blood mononucleic cells in models of CKD (Lajdova et al. 2012; 
Lajdova et al. 2017). Expression of P2X7 on such cells via ATP leads to release of 
interleukin-1B (IL-1B) and interleukin-18 (IL-18) which generate a pro-inflammatory 
environment conducive to kidney tissue degeneration, injury and cell death (Gentile et 
al. 2015; Pelegrin & Surprenant 2006; Fadok et al. 1998; Le Feuvre et al. 2002). This 
effect is mediated through activation of the NLPR3 inflammasome, potentially by a 
P2X7/P2X4/pannexin-1 complex that initiates pore formation, priming the cell for 
apoptosis (Pelegrin & Surprenant 2006; Solini et al. 2013; Hung et al. 2013). P2X7 
blockade actually protects against renal nephrotoxic injury by reducing inflammatory 
response, reducing apoptosis and the NLRP3 inflammasome (Yan et al. 2015; Zhang 
et al. 2014; Danquah et al. 2016). 
By regulating cell death in this way, P2X7 can regulate the turnover of the cells upon 
which it is expressed, including granulocytes (Le Feuvre et al. 2002; Wang et al. 2004). 
Leucocytes, such as granulocytes, are vital in the normal regulation of a sustained 
inflammation, and dysregulation can promote disease (Walker et al. 2005). Indeed, 
scid mice lacking lymphocytes show an attenuated hypertensive phenotype upon 
ANGII administration (Crowley et al. 2010). Furthermore, P2X7 deficient mice lack 
leukocyte responses to ATP seen in wild type mice and exhibit attenuated 
inflammatory responses, renal injury and hypertension (Labasi et al. 2002; Ji, Naito, 
Weng, et al. 2012). Add to this the finding that administration of the 
immunosuppressant, mycophenolate mofetil, in hypertensive mice leads to an 
attenuated PN response, the alteration of which is the driving force of salt-sensitive 
hypertension (Franco et al. 2013; Sathanoori et al. 2015; Stachon et al. 2017).  
P2X7 is functionally, if not structurally linked to P2X4 – a purinergic receptor with 
which it shares almost 50% homology in both the human and the rat (Craigie et al. 
2013). There is continued debate about whether or not P2X7 and P2X4 form 
heterotrimers (Guo et al. 2007; Antonio et al. 2011), however their functional 
relationship to each other within a renal environment is much clearer. A recent study 
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found increased expression of P2X4 in renal tubule cells from patients with diabetic 
nephropathy (Chen et al. 2013). P2X4-mediated activation of the NLRP3 
inflammasome in ex vivo cell studies and receptor expression had a strong positive 
correlation with renal excretion of IL-1B in diabetic patients. P2X4 also promotes 
apoptosis in human mesangial cells (Solini et al. 2013), a process that contributes to 
glomerular injury in chronic renal disease. P2X4 deficient mice are also protected 
against inflammation in models of arthritis (Li et al. 2014): its role in kidney disease 
is not clear as a recent study found that that P2X4 deficient mice displayed an 
exaggerated injury response to unilateral ureteric obstruction (UUO), a model of 
chronic renal inflammatory disease (Kim et al. 2014).  
P2X7 has also been linked to fibrosis, with activation of P2X7 leading to release of 
TGF-β and a resultant increase in extracellular matrix production in glucose treated rat 
mesangial cells (Solini et al. 2005; Gentile et al. 2015). Knock out of P2X7 in UUO 
mice also has a protective effect with reduction in TGF-β, fibrosis positive staining 
and inflammatory cell infiltration in P2X7-/- UUO mouse kidneys, compared to WT 
UUO. 
Despite substantial existing evidence supporting the inflammatory role of P2X7 in 
renal injury and disease, exploiting P2X7 antagonists in clinical trials for basic 
inflammatory diseases, such as rheumatoid arthritis, have failed, with no significant 
benefit of using the drug seen compared to the placebo (Arulkumaran et al. 2011; 
Keystone et al. 2012; Stock et al. 2012). This indicates that there are other pathways 
acting in such diseases that may act independently of inflammation to drive the 
pathological phenotype.  
1.5.3 P2X7 in the renal vasculature 
One promising complementary contributor of P2X receptors to renal disease is their 
vascular role. The vasoactive effects of nucleotides have been well-documented and 
whether constriction or dilation of vessels is stimulated depends on a number of 
factors. The source of ATP, location or type of P2 receptor and the basal vascular tone 
all influence the overall effect.  
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In terms of renal disease, P2 receptors are involved in key regulatory processes in the 
kidney which, if disrupted, can have significant effects on renal function. P2X1, for 
example, is a key mediator of autoregulation in the kidney (Inscho et al. 2003). Upon 
increased systemic blood pressure, increase in renal blood flow is buffered by P2X1-
mediated vasoconstriction in the afferent arteriole, protecting the glomerulus from 
pressure induced injury. Vessels from P2X1 null mice exhibit blunted vasoconstriction 
during the pressure-mediated autoregulatory response; this leads to failure of 
autoregulation and resultant barotrauma (Inscho et al. 2003).  
Autoregulation is a vital process in the kidney, but has been shown to be more effective 
in the cortex than the medulla, meaning a loss of haemodynamic control in this area 
(Cowley et al. 1992). An increase in BP in the medullary vasa recta leads to release of 
nitric oxide (NO) via a sheer stress response, which promotes sodium retention, 
leading to an impaired PN and thus hypertension and injury (O’Conner & Cowley Jr. 
2010). Indeed, inhibition of NO release under these circumstances reduces medullary 
blood flow (Mattson et al. 1992). However, NO inhibition does not alter the PN 
response, suggesting that NO is not the sole mediator of a renal injury observed 
following a medullary blood pressure increase. Under these circumstances, ATP and 
purinergic receptors may also contribute to a disease phenotype and evidence for this 
is building, including findings of P2X receptor expression in the microvasculature. 
P2X1, P2X4 and P2X7 have all been identified in rat renal vessels (Lewis & Evans 
2001) with P2X4 and P2X7 expression observed in the pre-glomerular 
microvasculature as well as in the smooth muscle of larger vessels (Menzies et al. 
2013). In human endothelial cells, P2X4 is identified as the most abundant P2X 
receptor, followed by P2X7 (Yamamoto et al. 2000). The observation of these 
receptors in both the smooth muscle and endothelial layers of vasculature imply direct 
roles in both signalling and vascular tone. These findings therefore strongly suggest a 
major role for P2X receptors in the renal vasculature, both physiologically and 
pathophysiologically. 
In terms of vasoactivity, P2X4 has a vasodilatory effect, consistent with its role in NO 
release (Yamamoto et al. 2006), but has also been shown to act in conjunction with 
P2X1 to cause sustained constriction in cerebral arteries and regulate vascular tone in 
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renal smooth muscle cells (Harhun et al. 2014; Harhun et al. 2010). P2X7 has been 
shown to cause vasoconstriction in rat retinal vessels via pericytes, with similar 
vasoactive roles suggested in the kidney, although experiments supporting this 
hypothesis are lacking (Kawamura et al. 2003; Menzies et al. 2013). Blockade of P2X 
receptors leads to altered control of pericyte-mediated vascular tone in the kidney 
(Crawford et al. 2013) and picking apart the role of each P2X subtype could give great 
insight into the contribution of these receptors to modulated vasoactivity and thus, BP 
and renal injury. 
Evidence of P2X vascular involvement in renal pathophysiology is also building. Both 
P2X4 and P2X7 have been identified via microarray analysis as key molecules in renal 
injury susceptibility in rodents, presenting a pathophysiological function (Menzies et 
al. 2013). P2X4 deficiency has been shown to induce loss of blood pressure control in 
response to altered blood flow, presenting a primary candidate for the correlation 
between renal ATP levels and vascular resistance (Nishiyama et al. 2000; Yamamoto 
et al. 2006). P2X1 and P2X7 have more recently been shown to contribute to the 
control of glomerular haemodyamics in models and ANGII-induced hypertension 
(Franco et al. 2017). P2X4 has also been identified as a receptor that mediates NO 
release under shear stress, meaning that its dysregulation could have severe effects of 
sodium and hence blood pressure control (Yamamoto et al. 2000). 
These studies provide evidence for the role of P2X receptors in renal vasculature 
control, with strong support that impaired control through these receptors may have 
consequences for PN, hypertension and resultant renal injury. This is shown by Ji and 
colleagues whereby P2X7 deficiency in DOCA-salt treated mice and P2X7 inhibition 
in Dahl salt-sensitive rats both lead to attenuated hypertension (Ji et al. 2012a; Ji et al. 
2012b). Furthermore, treatment of ANGII-induced hypertension in F344 rats with a 
highly selective P2X7 antagonist restores the PN response, normalises BP and 
improves renal oxygenation (Menzies et al. 2015). Finally, endothelial expression of 
P2X7 has been shown to be vital in the recruitment of Mac-1/ICAM-1 dependent 
leukocytes in a murine model of septic encephalopathy (Wang et al. 2015). Such 




P2X7 deficiency in mice has been implicated in lipopolysaccharide-induced vascular 
dysfunction, reducing downstream production of inflammatory agents (Chiao et al. 
2008; Chiao et al. 2013), further supporting the theory that P2X-mediated vascular 
dysfunction is the priming step in the setup of CKD. However, the vasoactivity of these 
receptors on different vessels and vascular surfaces needs to be further clarified before 
any solid mechanisms can be revealed: inflammatory or vascular.  
 
Figure 1.3 - Vascular and inflammatory pathways of establishing renal injury 
and the role that P2X4 receptors (R) andP2X7R may play in each. Expression of 
P2X4R and P2X7R on renal vascular may mediate vascular tone and hence renal blood 
flow and pressure. Increased expression of P2XR may lead to abnormal regulation of 
these functions and thus loss of microvasculature, hypoxia and renal injury. Expression 
of P2X4R and P2X7R on immune cells contributes to release and modulation of 
cytokines, such as interleukin (IL)-1β, IL-18. Upregulation of these P2XR may lead to 
increased inflammation, which results in renal injury. SMC, smooth muscle cell. 





1.5.4 P2X7 in clinical trials 
The arguments for the inflammatory roles of P2X receptors versus their vascular role 
in CKD have been proposed, yet the likelihood is that they work in conjunction, 
especially since clinical trials for the P2X7 antagonists, AZD9056 and CE-224,535 in 
inflammatory treatment have thus far failed to show any benefit over the placebo 
(Keystone et al. 2012; Stock et al. 2012). Although P2X7 antagonists have been shown 
to be well-tolerated in humans, inefficacy of the drug have prevented progression of 
these clinical trials beyond Phase 3 (Arulkumaran et al. 2011). There are further 
complications surrounding P2X7 which may account for this, such as its functional 
link to P2X4, or its splice variant profile. However, the problem may also be the 
intervention point of treatment in these trials. If P2X7 is indeed playing a role in very 
early time points of CKD, at the vascular level, then treatment with antagonists must 
be aligned with this phase of P2X7 activity. Elucidating the role of P2X7 in the 


















My hypotheses are: 
 
1. ANGII DOCA salt model (Figure 2.1) will capture phenotypes relevant to early 
CKD, specifically: hypertension, vascular dysfunction, limited inflammation, 
limited fibrosis. As this model represents early CKD, rather than late CKD, I 
do not expect to see adverse changes in renal function, such as glomerular 
filtration rate and renal blood flow 
 
2. P2X7 will be present in the renal vasculature of mice, particularly in cell types 
that play a role in modulation of vascular tone; endothelial cells, vascular 
smooth muscle cells and pericytes. From review of the literature, I hypothesise 
that P2X7 will be present at higher levels in the ANGII DOCA salt mouse 
model of vascular renal injury. 
 
3. Activation of P2X7 will induce a vasoconstriction of the isolated mouse aorta, 
exaggerated in ANGII DOCA salt animals. I hypothesise that antagonism of 
P2X7 will reduce this constrictive effect which will lead to a reduction in blood 
pressure and restoration of renal blood flow in ANGII DOCA salt mice. 
 


































All experiments were performed on C57BL6/J male mice between the ages of 10 – 16 
weeks (Charles River, UK). Mice were housed in the animal unit at Little France under 
controlled conditions of temperature (21±1°C), humidity (50±10%) and light/dark 
(light 7am–7pm). Mice had ad libitum access to water and a standard rodent chow 
(0.25% Na) unless otherwise specified. Procedures were performed in accordance with 
the UK Home Office Animals (Scientific Procedures) Act of 1986 after ethical review 
by The University of Edinburgh. 
ANGII, DOCA and salt diet administration 
Male C57BL6/J mice were split into two groups: sham; consisting of sham operated 
animals implanted with an osmotic minipump (Alzet, 2002 model) containing 0.9% 
saline, a blank pellet, receiving standard chow, and experimental; consisting of animals 
receiving ANGII (100ng/kg/min) via osmotic mini-pump, a deoxycorticosterone 
(DOCA, Sigma-Aldrich) pellet and receiving a 3% sodium chow (DBM Ltd). As per 
the timeline below, mice were implanted with minipumps and pellets on day 0, the 
experimental group received sodium chow on day 3 and all mice were culled or 
underwent experimental procedure on day 28. 
Four cohorts of mice have been carried out to date as detailed below (See Table 1). 
More details on experimental protocol can be found under the relevant methods and 
materials heading. Mortality rate across these cohorts currently stands at 5.3%. 
 











chow Cull or experiment  
Figure 2.1 - Timeline of Sham and ANGII DOCA salt mice from surgery at day 0 (T0) 
to cull at day 28 (T28) 
36 
 




1 6 Mice were culled via cervical dislocation and the kidneys 
and heart removed, weighed and either transferred to 4% 
PFA in preparation for IHC, or snap frozen in preparation 
for WB. 
2 12 Systolic blood pressure (SBP) measurements were made 
at baseline (before surgery, after training), 2 weeks (mid-
point) and 4 weeks (pre-terminal) via tail cuff 
pleismography. At day 28, mice underwent renal clearance 
surgery, after which they were culled by cervical 
dislocation. Kidneys and hearts were removed and 
weighed before disposal. 
3 10 Urine collections were taken from mice at baseline (before 
surgery), 2 weeks (mid-point) and 4 weeks (pre-terminal) 
through the use of 24-hour metabolic cages.  Mice were 
culled by exposure to CO2 and aortas and mesenteric 
arteries removed for myography. Kidneys, heart, spleen 
and liver were removed, weighed and halved – half was 
transferred to 4% PFA in preparation for IHC, and half 
frozen in preparation for WB and PCR. Aorta not needed 
for myography was also snap frozen for RNA extraction. 
4 16 Mice were culled by exposure to CO2 and aortas removed 
for myography. Kidneys were removed, weighed and 
homogenised for separation of cells via FACS. Aorta not 








C57BL6/J mouse kidneys in Sham or ANGII-DOCA salt mice, or from a WT 
C57BL6/J colony, were perfusion fixed with 4% paraformaldehyde (PFA) and 
incubated at 4°C in 4% PFA for 24 hours before replacing with 70% ethanol. Kidneys 
were paraffin embedded, dried and sectioned at 4µm. Following dewaxing, 
dehydrating and heat-induced epitope recovery (HIER) at 90°C with citrate buffer, 
sections were incubated with 0.1% Sudan black B solution (Sigma Aldrich), 0.1% 
Triton-X-100 (Sigma Aldrich) and 3% hydrogen peroxidase, each for 10 minutes. 
Sections were then blocked overnight at 4°C in 10% normal donkey serum. Sections 
were incubated in primary antibody for 2 hours at room temperature. Primary rabbit 
polyclonal antibodies against the P2X1 (1:500, APR-001, Alomone Labs), P2X4 (1: 
500, APR-002, Alomone Labs), and P2X7 ((i) intracellular targeting APR-004 at 
1:500 and (e) extracellular targeting APR-008 at 1:500, Alomone Labs) were used. 
After washing, sections were subjected to incubation with a peroxidase linked donkey 
anti-rabbit secondary antibody (1:750, Jackson Immuno Research) for 1 hour at room 
temperature and then incubation with a green tyramide amplification reagent (1:50, 
Perkin Elmer) for 10 minutes. Sections underwent a mild retrieval protocol via 
microwaving in citrate buffer before incubation with one of three second primary 
antibodies, overnight at 4°C, which are as follows: rabbit anti-CD31 (1:50, Abcam), 
rabbit anti-αSMA (1:250, Abcam) or rabbit anti-PDGFRβ (1:250, Abcam). The 
following day, sections were again subjected to incubation with a peroxidase linked 
donkey anti-rabbit secondary antibody (1:750, Jackson Immuno Research) for 1 hour 
at room temperature. Slides were finally incubated with a red tyramide signal 
amplification reagent (1:50, Perkin Elmer) before mounting with Vectashield DAPI 
medium (Vector labs). Images were taken using a Leica SP5 confocal microscope 
under the following channels and excitations/emissions: DAPI (blue); 405nm/482nm, 
FITC (green); 488nm/530nm and TRITC (red); 543nm/650nm. Images were analysed 






Measurement of fibrotic injury 
C57BL6/J mouse kidneys in sham (n=6) or ANGII DOCA salt (n=5) mice were 
perfusion fixed with 4% paraformaldehyde (PFA) and incubated at 4°C in 4% PFA for 
24 hours before replacing with 70% ethanol. Kidneys were paraffin embedded, dried 
and sectioned at 4µm. Following dewaxing and dehydration, slides were stained with 
Picrosirius red. Three sections were taken per kidney, at least 50 µm apart. Ten non-
overlapping images were taken per kidney across the cortex and medulla using an 
Olympus BX51 light microscope at a 20x objective. Images were analysed using 
Image J software by converting to an RGB stack and setting thresholds to detect red 
collagen staining. This was done for overall interstitial fibrosis and perivascular 
fibrosis. For the latter, area fibrosis (pixels) was normalised to the mean of each vessel 
thickness (pixels). Data are presented as mean ± s.d area collagen staining (AU) per 
20x image. Statistical analysis was performed by unpaired t-test. 
ELISAs 
Urine from both Sham (n=10) and ANGII DOCA salt (n=9) mice at baseline and pre-
terminal time points were analysed via commercial ELISA kits for albumin (Mouse 
Albumin ELISA Kit; Abcam), KIM-1 (Mouse TIM-1/KIM-1/HAVCR Quantikine 
ELISA Kit; R&D Bioteche) and 8-isoprostane (8-Isoprostane ELISA Kit; Cayman 
Chemical). For 8-isoprostane analysis, samples were treated with butylated hydroxyl-
toluene (BHT, 0.005%) upon collection and immediately frozen at -80°C. For KIM-1 
and albumin ELISA analysis, samples were immediately frozen after collection at -
20°C. Data are presented as mean ± s.e.m. Statistical analysis was performed by 
unpaired t-test. 
qPCR 
RNA extraction from frozen kidney and aorta samples was carried out using the 
RNAeasy Micro Kit (Quiagen). RNA integrity was checked by running RNA samples 
on a 1.2% agarose gel containing 0.6% ethidium bromide for 2 hours at 100V and 
visualising bands under UV light. RNA quantity was measured using the Nanodrop-
1000 spectrophotometer (Labtech International). 1µg of RNA was used to generate 
cDNA using Applied Biosystem High Capacity cDNA Reverse Transcription Kits 
(Thermo Fischer Scientific). Taqman gene assays (Thermo Fisher Scientific) were 
used in conjunction with the Lightcycler 480 (Roche) to measure mRNA levels of 
various genes between Sham (n=10) and ANGII DOCA salt (n=8) mouse kidneys; 
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probes detailed in the table below (See Table 2.2). Data are presented as mean ± s.e.m. 
Statistical analysis was performed by unpaired t-test. 
Table 2.2 - Taqman probes used in qPCR 
Gene NCBI Reference Target Sequence Cat # 
hprt NM_013556.2 Mm_03034075_m1 
kim-1 NM_001166631.1 Mm_00506686_m1 
col1a1 NM_007742.3 Mm_00801666_g1 
col3a1 NM_009930.2 Mm_01234476_m1 
cd68 NM_001291058.1 Mm_00839636_m1 
arg1 NM_007482.3 Mm_00475988_m1 
nos2 NM_010927.3 Mm_00440502_m1 
il1β NM_008361.3 Mm_01336186_m1 
cd31 NM_001305158.1 Mm_01242584_m1 
acta2 NM_007392.3 Mm_00725412_m1 
pdgfrβ NM_008809.2 Mm_00735546_m1 
p2x7r NM_011027.3 Mm00440578_m1 
 
End Point PCR 
RNA extraction from frozen kidney samples was carried out using the RNAeasy Micro 
Kit (Quiagen). RNA integrity was checked by running RNA samples on a 1.2% 
agarose gel containing 0.6% ethidium bromide for 2 hours at 100V and visualising 
bands under UV light. RNA quantity was measured using the Nanodrop-1000 
spectrophotometer (Labtech International). 1µg of RNA was used to generate cDNA 
using Applied Biosystem High Capacity cDNA Reverse Transcription Kits (Thermo 
Fischer Scientific).  
A KOD Hotstart PCR Kit (INFO) was used to amplify p2x7 gene variants as detailed 
in the table below (Table 2.2). Resultant cDNA was then ran on a 1.2% agarose gel 
containing 0.6% ethidium bromide for 1.5 hours at 80V, with bands visualised under 
UV light. Primers were used to observe the presence or absence of p2xr7 variants in 
Sham kidneys (n=7), ANGII DOCA salt kidneys (n=7), Sham aorta (n=8) and ANGII 
DOCA salt aorta (n=8). 
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Table 2.2 - p2xr7 primers used for end-point PCR 
Gene NCBI Reference 
Target Sequence 






NM_011027.3 FWD:  5' - 
CTGTGTGCATTGAC 
TTGCTC - 3’ 
REV:   5' - 
CAGTAGGGATACT 




NM_001038845.2 FWD:  5' - 
CTGTGTGCATTGAC 
TTGCTC - 3’ 
REV:    5'-
TCAGGTGCGCATAC 
ATACATG - 3’ 
62°C 286bp 
 
FACS analysis of kidneys 
Kidneys from Sham (n=6) and ANGII DOCA salt mice (n=6) were halved, diced and 
added to a digestion buffer comprised of collagenase V (Sigma), collagenase D 
(Roche), dispase (Gibco) and DNase (Roche). This mixture was then incubated at 
37°C for 45 minutes. Samples were then immediately removed to ice and 2ml ice-cold 
FACS buffer (2% FBS in PBS) was added. This solution was then filtered at 70µm 
and 40µm before spinning at 500xg at 4°C for 5 minutes. The resultant cell pellet was 
incubated for 1 minute with red blood cell lysis buffer before adding 15ml ice-cold 
FACS buffer.  This solution was again spun at 500xg at 4°C for 5 minutes. Cell pellets 
were resuspended in 1ml FACS buffer. Fc receptors were blocked at 4oC for 20 
minutes with anti-mouse or anti-human CD16/CD32 antibody (BD Biosciences). 
Primary conjugated antibodies (PE-PDGFRβ - Biolegend, BV-CD31 - Biolegend, 
CY7-F4/80 - eBioscience and FITC-LTL - Vector) were added to the samples at 1:100, 
before vortexing and incubating at 4°C for 30 minutes. Cells were then washed in 
FACS buffer before cell sorting using an Aria FACS sorter (BD Biosciences). Analysis 
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was carried out using FlowJo analysis software. FMO controls were included for each 
fluorescent antibody used. 
Western blot 
Whole kidneys were homogenized in 250mmol/L sucrose, 10mmol/L triethanolamine 
isolation buffer with added protease inhibitors (Cocktail set III, Thermoscientific). 
Following quantification of total protein content of each kidney sample by BCA 
Protein Assay Kit (Pierce), samples were added to Laemli buffer containing 2-
mercaptoethanol and 48μg of each sample separated by SDS-PAGE on Precise Protein 
12% gels (Thermoscientific). A segment of gels was taken for Coomassie staining and 
the remainder subject to semi-dry transfer after which the membranes were blocked in 
skimmed milk and incubated overnight at 4°C with primary antibody. Primary rabbit 
polyclonal antibodies against the P2X1 (1:100, APR-001, Alomone Labs), P2X4 (1: 
1000, APR-002, Alomone Labs), and P2X7 ((i) intracellular targeting APR-004 at 
1:500 and (e) extracellular targeting APR-008 at 1:500, Alomone Labs) were used. A 
goat-antirabbit HRP secondary antibody (1:10,000, Santa Cruz Biotechnology) was 
then added and the bands visualized by ECL. Band intensity was quantified by 
densitometry using ImageJ software(Schindelin et al. 2012). Values were normalized 
to the total protein intensity (as visualised by Coomassie staining) at the appropriate 
molecular weight. Data are presented as mean ± s.e.m. Statistical analysis was 
performed by unpaired t-test, normal distribution assumed. 
Renal Functional Studies 
Mice were anaesthetized with an IP injection of thiabutabarbital sodium salt hydrate 
(110mg per kg BW). Supplemental doses of anaesthesia were administered as required 
by monitoring toe reflex. Once a stable level of anaesthesia was obtained, mice were 
placed on a surgical table with servocontrol of temperature to maintain body 
temperature at 37°C. Renal clearance studies were performed as previously described 
(Zhao & Navar 2008). After shaving the incision site, a tracheotomy was performed 
with polyethylene (PE)-90 tubing. The right jugular vein was cannulated with PE-10 
tubing and a bolus injection of isotonic saline given. The right carotid artery was 
cannulated with PE-10 tubing for continuous measurement of BP and blood sampling. 
BP was recorded continuously at 1 kHz via a brass transducer (MLT844; Capto) 
connected to a Powerlab (AD Instruments). After surgery, an isotonic saline solution 
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containing 0.25% FITC Inulin and 0.5% PAH was infused at 0.2mL/10 g BW/hour. 
After a 60-minute equilibration period, urine was collected for 40 minutes. Either 
AZ11657312 (6.2mg/kg) (Sham; n=6, ANGII-DOCA salt; n=4) or 0.1% DMSO 
vehicle (Sham; n=5, ANGII-DOCA salt; n=4) was then injected intravenously. A 
subsequent urine collection of 40 minutes was then performed.  Plasma samples were 
taken before and after each urine collection period with a terminal plasma sample 
being taken at the end of the experiment. Inulin-FITC and PAH assays were carried 
out as previously described to determine concentration (Lorenz & Gruenstein 1999; 
Bratton & Marshall 1939; Smith et al. 1945). 
The following calculations were then used to determine renal functional values: 
Cx = (Ux x V) / Px 
Cinulin = GFR 
CPAH = eRPF = RPF x 0.9 
RBF = (eRPF/0.9) x (1/[1-haematocrit]) 
FEx = (Ux x Pinulin) / (Px x Uinulin)  
UV = V x Ux 
RVR = MABP/RBF 
Where:  
C = clearance 
x = cleared substance 
U = urinary concentration  
V = flow  
UV = urine flow  
P = plasma concentration 
eRPF = effective renal plasma flow 
RPF = renal plasma flow 
RBF = renal blood flow 
Inulin = FITC-inulin  
PAH = para-aminohippuric acid 
FEx = fractional excretion of x 
RVR = renal vascular resistance 
MABP = mean arterial blood pressure, measured under anaesthesia 
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Data are presented as mean ± s.e.m. Statistical analysis was performed by unpaired t-
test. 
 
Vascular Tone Studies 
Vascular contractile force was measure by wire myography of C57BL6/J mouse 
vessels. Mice were asphyxiated with CO2 and the aorta was isolated and placed in ice 
cold physiological salt solution (PSS; 119.0mM NaCl, 3.7mM KCl, 2,5mM CaCl2, 
1,2mM MgSO4, 25.0mM NaHCO3, 1.2mM KH2PO4, 27.0μM EDTA, 5.5mM D-
glucose). Vessels were cleaned of fat, cut into 1mm rings and mounted onto a wire 
myograph (Danish MyoTech). The wells each contained 6ml PSS perfused with 95% 
O2 and 5% CO2 at a temperature of 37°C. The vessels were stretched to a basal tone 
(aortas: 7.34mN) and left to equilibrate for at least 30 minutes before setting the 
baseline measurement to 0mN. Initial contractility was measured by adding 125mM 
KCl (KPSS) to each well in place of PSS. For measurements of changes in vessel 
function in ANGII DOCA salt mice, compared to Sham (ANGII DOCA salt mice; 
n=9, Sham mice; n=10), vessels were subject to phenylephrine (PE, Sigma; 1x10-9 – 
1x10-6M), acetylcholine (Ach, Sigma; 1x10-9 – 1x10-5M) and sodium nitroprusside 
(SNP, Sigma; 1x10-9 – 1x10-5M). These mouse vessels were then split into groups 
treated with either P2X7 antagonist A438079 (Tocris) at 10μM (ANGII DOCA salt; 
n=5, Sham; n=5) or vehicle (ddH2O) of the same volume (ANGII DOCA salt mice; 
n=4, Sham; n=5). Vessels were then subject to a single dose of P2X7 specific agonist 
BzATP (Tocris) at 50μM and the resultant vascular constriction monitored. This study 
was repeated with the same protocol, using larger group sizes - P2X7 antagonist 
A438079 (Tocris) at 10μM (ANGII DOCA salt; n=8, Sham; n=8) or vehicle (ddH2O) 
of the same volume (ANGII DOCA salt mice; n=8, Sham; n=8).  
A separate vascular tone study to monitor the effects of BzATP on endothelial cell 
mediated constriction was also carried out. The same protocol for this study was used, 
with the exclusion of the use of P2X7 antagonist A438079 and the exclusion of SNP. 
In this study, all aortas were from male C57BL6/J mice aged 10 weeks. Before 
mounting vessels onto the myography half of the vessels were denuded (n=8) and the 
endothelium mechanically removed via rubbing a metal insect pin across the inside of 
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the vessel. The other half of the vessels, i.e. intact vessels (n=8) were undisturbed 
before mounting. 
Data is presented as mean percentage ± s.d of KPSS response for contractile responses, 
or as mean percentage of max preconstriction ± s.d for dilatory responses, plotted 
against –log concentration. Statistical analysis was performed by two-way ANOVA 
with Bonferroni post-hoc test where appropriate. 
Statistical Analysis 
Analysis was carried out on GraphPad Prism 5.0. Outliers, as determined as outside 
the range of two standard deviations from the mean, were excluded from data analysis. 













































Chapter 3: Establishment and 
characterisation of an ANGII DOCA 





















In order to study the role of P2X7 in early CKD, it was necessary to establish and 
characterise a mouse model representative of this stage of disease. The model chosen 
was a variation of the angiotensin deoxycorticosterone salt (ANGII DOCA salt) model 
first described by Kirchhoff and colleagues in 2008 (Kirchhoff et al. 2008). This model 
involved a 3-week study of uninephrectomised mice on a high salt diet and implanted 
with an ANGII minipump and DOCA pellet. This group saw heavy fibrosis with high 
blood pressure, inflammation and albuminuria, which far surpassed the level of injury 
required for our criteria. We therefore modified this model, forgoing the 
uninephrectomy and reducing the ANGII dose 10-fold, from 1000ng/kg/min to 100 
ng/kg/min. The study was also limited to 4 weeks, in order to maintain the chronic 
nature of the disease. Control mice were sham operated, implanted with a saline 
minipump and blank pellet in place of DOCA, and were kept on standard chow.  
A full characterisation of the model was then undertaken, with the eventual intention 


















3.2 Hypothesis and Aims 
From pilot studies and review of the relevant literature, I hypothesise that the ANGII 
DOCA salt model (Figure 3.1) will capture phenotypes relevant to early CKD, 
specifically: 
• Hypertension 
• Vascular dysfunction 
• Limited inflammation 
• Limited fibrosis 
As this model represents early CKD, rather than late CKD, I do not expect to see 
adverse changes in renal function, such as glomerular filtration rate and renal blood 
flow. 
The aim of this study is to measure the above criteria through a combination of ex vivo, 














Figure 3.1 - Timeline of Sham and ANGII DOCA salt mice from surgery at day 0 (T0) 
to cull at day 28 (T28) 












Kidneys removed for 
histological analysis/RNA 
extraction/flow cytometry and 
aortas removed for myography 
OR 
Mouse underwent renal 
clearance surgery for assessment 















3.3.1 ANGII DOCA salt mice exhibit mild hypertension and changes in sodium and 
potassium handling, without altering renal function 
Over the 4-week experiment, sham mice gained weight, whereas ANGII DOCA salt 
mice did not and were significantly lighter by week 4 than controls (ANGII DOCA 
salt:  28.8±0.47g, Sham: 31.5±0.34g at Week 4). ANGII DOCA salt mice also 
exhibited increased kidney weight compared to Sham (ANGII DOCA salt: 
0.072±0.009g/10gBW, Sham: 0.054±0.007g/10gBW at cull) – an effect that was not 
observed in heart, liver or spleen (Figure 3.2; Figure 3.4). 
ANGII DOCA salt mice were also mildly hypertensive with an increased systolic 
blood pressure (ANGII DOCA salt: 136.5±3.2mmHg, Sham: 113.3±1.9mmHg) but no 
other significant renal haemodynamic changes were observed (Figure 3.2), when using 
blood pressure measured under anaesthetic for calculations (Table 3.1).  
There was no change in sodium excretion between groups although fractional sodium 
excretion showed a trend for a small increase in ANGII DOCA salt mice compared to 
Sham (Figure 3.4). Haematocrit was increased, but not to a significant level (Figure 
3.4). A small trend for a decrease in potassium excretion was observed in ANGII 
DOCA salt mice compared to Sham. However, plasma potassium concentrations were 
significantly lower in ANGII DOCA salt mice compared to Sham (Table 3.1) and GFR 
showed a trend to decrease in ANGII DOCA salt mice compared to Sham (Figure 3.2). 
Therefore, using these parameters to calculate the resultant fractional potassium 
excretion led to an observed 2-fold increase in the ANGII DOCA salt group compared 


















Figure 3.2 - Entire body weight and organ weights in Sham and ANGII DOCA 
salt mice. (A) Entire body weight of Sham (blue, n=28) and ANGII DOCA salt 
(red, n=24) mice at weekly time points over 28-day study. Data are mean ± SD, 
analysed by two-way ANOVA, *p<0.05, **p<0.01, ***p<0.001. (B) Heart 
weights, (C) right kidney weights, (D) left kidney weights, (E) liver weights and 
(F) spleen weights at day 28 in grams (g), normalised to 10g body weight (BW) in 
Sham (blue, n=26) and ANGII DOCA salt (red, n=22) mice. Data are mean ± 95% 








Figure 3.3 - Blood pressure, glomerular filtration rate, renal blood flow and renal 
vascular resistance in Sham and ANGII DOCA salt mice. (A) Systolic blood 
pressure (SBP) in ANGII DOCA salt (red, n=11) and Sham (blue, n=12) mice. Data 
are mean ± SD, analysed by two-wayANOVA, ***p<0.001. (B) Glomerular filtration 
rate (GFR) normalised to kidney weight, (C) renal blood flow (RBF) normalised to 
kidney weight and (D) renal vascular resistance (RVR) in ANGII DOCA salt (red , 




























Figure 3.4 – Sodium and potassium handling in Sham and ANGII DOCA salt 
mice. (A) Sodium excretion, (B) potassium excretion, (C) fractional sodium excretion, 
(D) fractional potassium excretion, (E) urine flow rate and (F) haematocrit in ANGII 
DOCA salt mice under anaesthesia (red , n=5) and sham (blue , n=5). Data are mean 




Table 3.1 – Blood pressure and plasma concentrations of sodium and potassium 
in Sham and ANGII DOCA salt mice 
Data are mean ± S.E.M. Data analysis by standard t-test. 






74.2±1.9 75.4±1.7 0.5232 
Sodium plasma 
concentration (mmol) 
145.2±1.0 151.4±2.1 0.0794 
Potassium plasma 
concentration (mmol) 
3.9±0.1 1.5* 0.0079 
* All plasma potassium measurements made in ANGII DOCA salt mice were below 
the lower limit of detection of equipment used. For the purpose of further 















3.3.2 ANGII DOCA salt mice exhibit increased urinary biomarkers of injury and whole 
kidney macrophage marker as well as increased levels of PDGFRβ positive cells and 
renal perivascular fibrosis  
Injury marker kidney injury molecule 1 (KIM-1) is increased at the mRNA level in 
whole kidney (ANGII DOCA salt: 1.17±0.5, Sham: 0.28±0.1) as well as at the protein 
level in urine (ANGII DOCA salt: 18.5±3.2ng/24H, Sham: 6.7±1.0ng/24H) at pre-
terminal time points in ANGII DOCA salt mice compared to Sham mice (Figure 3.5). 
ANGII DOCA salt mice also have increased levels of albuminuria (ANGII DOCA 
salt: 357.3±23.2μg/24H, Sham: 22.0±2.1μg/24H) at pre-terminal time points, whereas 
levels of 8-isoprostane, a marker of oxidative stress, remained constant between 
groups (Baseline - ANGII DOCA salt: 43.54±4.9pg/24H, Sham: 55.75±4.5pg/24H, 
Pre-terminal - ANGII DOCA salt: 68.85±6.4pg/24H, Sham: 51.65±8.7pg/24H). In 
mRNA from whole kidney homogenates, collagen 1 (col1a1) marker was increased in 
ANGII DOCA salt mice compared to sham, but collagen 3 (col3a1) (Figure 3.6) was 
not. Upon investigation at the protein level through immunohistochemistry, collagen 
deposition was observed at significantly increased levels in perivascular, but not 
interstitial areas in ANGII DOCA salt mouse kidneys (ANGII DOCA salt: 
54.9±3.7pixels, Sham: 40.2±3.2pixels normalised to vessel thickness; Figure 3.6). 
Collagen deposition was not observed in glomeruli (data not shown). Pan-macrophage 
marker, cd68, was also upregulated in ANGII DOCA salt mice at the mRNA level 
compared to sham, although there was no change in M1 or M2 specific markers (nos 
2and arg1 respectively). There was also no change in markers for vessel density 
(endothelial marker pecam-1 and smooth muscle marker acta2) or pericytes (pdgfrβ) 
between the two groups (Figure 3.5). 
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Figure 3.5 – Urinary and whole kidney injury markers in Sham and ANGII 
DOCA salt mice. (A) Urinary protein levels of albumin, (B) urinary protein levels of 
8-isoprostane and (C) urinary protein levels of KIM-1 at baseline and pre-terminal 
time points of ANGII DOCA salt mice (red, , n=8) and sham (blue , n=10). (D) 
Whole kidney mRNA levels of hepatitis a virus cellular receptor 1 (havcr1; gene for 
KIM-1 protein) at cull. Data are mean ± 95% CI. mRNA kim-1 data analysed by t-test, 
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Figure 3.6 – Collagen marker levels in Sham and ANGII DOCA salt mice.  
(A) Whole kidney mRNA levels of collagen type 1 (col1a1) and (B) collagen type 3 
(col3a1) in ANGII DOCA salt mice (red, , n=6-8) and sham mice (blue , n=10). 
Data are mean ± 95% CI. Kidney sections were stained immunohistologically for 
collagen by picrosirius red (PSR). Images are (C) interstitium and (D) perivascular 
areas of Sham (blue, n=5, 3 sections per animal, 10 images per section) and ANGII 
DOCA salt (red, n=4, 3 sections per animal, 10 images per section) mice. 
Quantification of pixels positive for collagen in (E) the interstitium and (F) 
perivascular areas (normalised to vessel diameter) of ANGII DOCA salt and Sham 































Figure 3.7 – mRNA levels of macrophage markers and vascular density markers 
in Sham and ANGII DOCA salt mice. mRNA  levels of (A) pan-macrophage marker 
cd68, (B) M1 macrophage marker nitric oxide synthase2 (nos-2), (C) M2 macrophage 
marker arginase 1 (arg-1), (D) pericyte marker platelet derived growth factor receptor 
b (pdgfrb), (E) endothelial marker platelet endothelial cell adhesion molecule 1 
(pecam-1) and (F) vascular smooth muscle marker alpha actin 2 (acta-2) all 
normalized to hprt housekeeper gene in ANGII DOCA salt mice (red, , n=8) and 
sham (blue , n=10). Data are mean ± 95% CI, analysed by t-test. 
 
Flow cytometry was also performed on kidney homogenate from Sham and ANGII 
DOCA salt mice, with separation of tubular cells (LTL +ve), endothelial cells (CD31 
+ve), macrophages (F4/80 +ve) and pericytes (PDGFRβ +ve) (Figure 3.8). Counts 
for tubular cells, endothelial cells and macrophages did not change, however, 
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Figure 3.8 – Gating strategy for the separation of endothelial cells (CD31 +ve), 
macrophages (F4/80 +ve), tubular cells (LTL +ve) and pericytes (PDGFRβ +ve) 
Demonstration of the gating strategy used to separate cells, with boxes denoting the 
events identified within the appropriate parameters and arrows following the step by 









Cells Singlets Live 
CD31+ve, 
F4/80 +ve LTL +ve PDGFRβ +ve 
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 Figure 3.9 – Cell counts of endothelial cell, macrophages, tubule cell and 
PDGFRβ +ve cell in Sham and ANGII DOCA salt mice. Cell counts of (A) 
CD31 +ve endothelial cells, (B) F4/80 +ve macrophages, (C) CD31 –ve, 
F4/80 –ve, LTL +ve tubule cells and (D) CD31 –ve, F4/80 –ve, LTL –ve, 
PDGFRβ +ve pericytes expressed as percentage live cells in ANGII DOCA 
salt mice (red, , n=11) and sham (blue , n=12). Data are mean ± 95% CI, 
analysed by t-test. (E) A visual example of raw data showing increased CD31 
–ve, F4/80 –ve, LTL –ve, PDGFRβ +ve cell count events in an ANGII DOCA 










3.3.3 Aortas from ANGII DOCA salt mice are hyper-responsive to both phenylephrine 
and acetylcholine, but not sodium nitroprusside 
In aortas from ANGII DOCA salt mice, contractile response to phenylephrine (PE) 
was increased compared to those from Sham mice, as was endothelium-dependant 
dilatory response to acetylcholine (Table 3.3;Figure 3.10). However, smooth muscle-
mediated vasodilator sodium nitroprusside (SNP) was the same in both groups (Table 
3.3; Figure 3.10). 
 
Figure 3.10 – Dose response curves of aortas from Sham and ANGII DOCA salt 
mice to phenylephrine, acetylcholine and sodium nitroprusside. Response of aortas 
from ANGII DOCA salt mice (red, , n=8) and Sham mice (blue , n=10) to (A) 
vasoconstrictor phenylephrine (PE), displayed as percentage force (mN) of maximum 
force (mN) as determined by (125mM) KCl response, and vasodilators (B) 
acetylcholine (Ach) and (C) sodium nitroprusside (SNP), displayed as percentage 
force (mN) of force (mN) at EC50 PE. Data points are mean ± SD with non-linear 
regression. All data are analysed by two-way ANOVA. (D) Response of same vessels 
to 125mM KPSS displayed as force in millinewtons (mN). Data points are mean ± 







Table 3.3  - EC50 and maximal responses of vessels to vasoactive pharmacological 
agents. EC50 expressed as – log [concentration in M] and maximal response of aorta 
from Sham and ANGII DOCA salt mice to phenylephrine (PE; 1.0E-6M), acetylcholine 
(Ach; 1.0E-5M), sodium nitroprusside (SNP; 1.0E-5M) and 125mM KCl. PE responses 
are expressed as %KCl response, Ach and SNP responses are expressed as 100 – % 
relaxation, KCl responses are expressed in millinewtons (mN). Data are mean±S.E.M. 
Group 



















Sham 6.36 89.96±11.9 68.98±7.5 118.83±4.1 2.45±0.25 
ANGII 



















In 2008, Kirchhoff and colleagues established a novel model of renal fibrosis in renal 
injury-resistant C57BL6 mice. Combining a uninephrectomy, administration of high 
doses of ANGII and DOCA and a high salt diet, the resultant phenotype included 
moderate hypertension, significant albuminuria, heavy interstitial fibrosis and 
increased infiltration of macrophages (Kirchhoff et al. 2008). Kirchhoff’s model has 
been used in the study of endoplasmic reticulum stress inhibition and prostaglandin 
receptor biology in hypertension in rodents (Mohammed-Ali et al. 2017; Bartlett et al. 
2012).  
This model differs from other models of renal injury such as uninephrectomy, ANGII 
or DOCA-salt in that it takes numerous components from all of the above to build a 
multi-factorial model of fibrosis. Individually, DOCA acts to increase salt appetite and 
to act as a precursor for aldosterone, promoting sodium reabsorption, all of which is 
augmented with the addition of a high salt diet. ANGII adds to this, not only by 
increasing aldosterone release, but by acting as a potent vasoconstrictor and vascular 
remodelling factor. CKD is, in itself, a multifactorial disease, often without a single 
underlying causation and so combining these factors in a multi-factorial approach in 
rodents may be a more accurate reflection of human disease (Gansevoort et al. 2013; 
Norman & Fine 2006; Long et al. 2012; Bidani et al. 2013).  
In this study, we used Kirchhoff’s model as a basis from which to establish a model of 
renal vascular dysfunction in mice, with the ANGII and DOCA salt components well 
defined as contributors to vascular dysfunction (Monassier et al. 2006). However, our 
criteria were to promote vascular dysfunction, hypertension and mild injury, without 
inducing heavy interstitial fibrosis or distinct changes in renal function as defined by 
significant changes in GFR and RBF. We therefore omitted the uninephrectomy and 
reduced the ANGII dose 5-fold to 100ng/kg/day, although the DOCA administration 
was kept the same (50mg pellet). 
In this study, hypertension was still established, but to a much smaller degree than that 
seen in Kirchhoff’s study, with ANGII DOCA salt mice exhibiting a mild increase in 
systolic blood pressure of approx. 25 mmHg opposed to the 50mmHg Kirchhoff and 
colleagues observed. As would be expected in mice fed a high salt diet, sodium 
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handling in ANGII DOCA salt mice was mildly altered. The potassium plasma 
concentrations reported, however, were not realistic representations of actual 
concentrations, as they were below the limit of lower detection of 1.5mmol. Plasma 
levels that are this low would cause serious side effects and mortality in mice, which 
were not observed. I therefore expect that this inaccuracy is due to the equipment used, 
which was designed for clinical use, rather than animal use. Research into more 
appropriate and accurate methodology is required. Haematocrit was slightly, but not 
significantly, increased in ANGII DOCA salt mice compared to Sham, indicating a 
possible decrease in plasma volume, and a potential effect on calculating renal blood 
flow and renal plasma flow. However, as the difference in haematocrit did not reach 
significance between the groups, this was not considered moving forwards with renal 
clearance calculations. 
Kidney weight was increased in ANGII DOCA salt mice compared to Sham, which 
indicates fibrosis, however, this result is not reliable, as the kidney weights were 
normalised to body weights, a data set that differed significantly between Sham and 
ANGII DOCA salt mice, with ANGII DOCA salt mice exhibiting a drop in body 
weight over the 4 week study and Sham mice maintaining their body weight. I would 
suggest that in future studies, tibias be taken at Week 4 after cull and used to normalise 
kidney weight, as this is a measurement that should not differ between groups.  
Injury marker, KIM-1 was increased, both at whole kidney mRNA level and protein 
level in urine in ANGII DOCA salt mice, indicating injury of the renal tubules. The 
increase, however, was about 2-3 fold, much lower than increases usually seen in 
kidney injury models, suggesting only mild injury.  ANGII DOCA salt mice also 
exhibited significant albuminuria consistent with an increase in intraglomerular 
pressure and/disruption of the glomerular filtration barrier. This observation was 
coupled with an increase in mRNA levels of collagen isoform col1a1, although col3a1 
remained unchanged. Upon immunohistochemistry investigation, collagen deposition 
was limited to perivascular areas, and not evident at high levels in the interstitium, or 
at all in glomeruli. ANGII DOCA salt mice also exhibited a small trend for decreased 
GFR and RBF with a resultant increase in RVR, which did not reach significance. 
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These observations all point to a low level of fibrosis and injury in the kidney. 
Upregulation of KIM-1 suggests tubulointerstitial injury, yet interstitial fibrosis is not 
yet established after 4 weeks of treatment in ANGII DOCA salt mice. It does signify, 
however, that the molecular mechanisms that contribute to fibrosis are in play and it 
may be that that the perivascular fibrosis seen in this model is the beginning of the 
fibrotic events that triggers the kidney into a cycle of disease progression. This would 
concur with Fine’s hypoxia hypothesis in which it is thought that the degeneration of 
the kidney begins with glomerular injury, which leads to loss of microvasculature, 
hypoxia and fibrosis, with primarily a vascular origin (Fine et al. 1998).  
However, levels of endothelial marker, pecam-1, were unchanged at the mRNA level, 
suggesting negligible loss of microvasculature. This data was supported by the 
observation that, upon FACS sorting of kidney homogenate from ANGII DOCA salt 
and Sham animals, CD31+ve counts were unchanged between groups. Tubular 
LTL+ve counts were also maintained, which was expected, given the lack of interstitial 
fibrosis and maintenance of physiological kidney function as defined by GFR and 
RBF. F4/80+ve counts for macrophages also remained constant which was 
unsurprising as infiltrating macrophages are a key marker of tubulointerstitial fibrosis, 
although mRNA macrophage marker cd68 was increased, suggesting a shift in 
molecular signalling of macrophages, if not an increase in actual number.  
Perhaps most interestingly, PDGFRβ+ve counts for pericytes are upregulated in 
ANGII DOCA salt mice. This could be an interpretation of an increase in vascular 
pericyte number, which may occur as a result of vascular injury. Immunostaining for 
PDGFRβ in ANGII DOCA salt mouse kidney does show a strong localisation of the 
pericyte marker at perivascular areas (See Chapter 4).  
It has been shown that pericytes can differentiate into myofibroblasts (Abraham et al. 
2007), the primary cells that deposit collagen in fibrosis, and that blocking PDGFR 
related pathways can attenuate fibrosis in a rodent UUO model of fibrosis (Lin et al. 
2011). It may be that there is an upregulation of pericytes in the kidney in this model, 
which leads to an increased transformation into and presence of myofibroblasts, firstly 
at perivascular areas, which deposit collagen in this area, starting fibrosis progression. 
However, there was no change seen in mRNA markers pdgfrβ for pericytes or acta-2 
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for myofibroblasts. This observation, paired with the fact that PDGFRβ is not entirely 
pericyte specific, warrants further exploration of pericyte markers at the protein level, 
such as CD146 or NG2, and myofibroblast marker αSMA, in order to confirm this 
theory. Other cell types, such as vascular smooth muscle cells are also PDGFRβ 
positive and are also suspects for increase in cell number in models of renal injury. 
Further distinguishing these cell types through identification of more pericyte or 
vascular smooth muscle cell specific markers through IHC or more FACs would 
greatly help in accurately identifying the cell type(s) of interest in this model. 
The FACs data shown here incorporates FMO controls to account for background 
fluorescents and normalises to % live cells. However, sample weights were not taken 
before processing for FACs analysis. To confirm results in future as absolute results 
rather than relative one, I would weigh kidneys in order to determine cell number and 
ensure a more reliable normalisation method.    
ANGII DOCA salt mice also exhibited significant vascular dysfunction, through 
hyper-reactivity of aortas to phenylephrine (PE) and acetylcholine (Ach). PE, a 
vasoconstrictor, acts on α1 adrenergic receptors on smooth muscle, which have been 
shown to be upregulated upon ANGII administration (Hu et al. 1995; Abdulla et al. 
2011), which may explain the hyper-reactivity of vessels from ANGII DOCA salt mice 
to PE. ANGII also has a significant effect on vascular remodelling, increasing vascular 
density through smooth-muscle mediated hypertrophy (Hatakeyama et al. 1994; 
Montezano et al. 2014), so the PE receptor population could also be increased through 
increased smooth muscle mass within vessels. Further investigation into these receptor 
populations would be required to explain this phenomenon. Acetylcholine and SNP 
are both vasodilators, with Ach acting in an endothelial dependent manner and SNP 
acting in an endothelium independent manner. Hyper-reactivity was observed in 
ANGII DOCA salt aortas in response to Ach, but not SNP, suggesting that changes in 
vasodilatory capacity of vessels is due to changes within the endothelium, possibly 
through modulation of the endothelial nitric oxide synthase (eNOS) pathway by 
ANGII, which is linked to Ach receptor activation (Förstermann & Münzel 2006). 
Again, further investigation into single components of this pathway would be required 
in order to elucidate the mechanism behind this.  
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Finally, there was a small increase in pan-macrophage marker, cd68, in whole kidney 
of ANGII DOCA salt mice, which could not be defined as either pro-inflammatory M1 
or alternatively activated M2 phenotype through measurements of respective markers 
nos2 or arg1, suggesting only a small amount of macrophage infiltration in ANGII 
DOCA salt mice kidneys. This is only a small indicator of inflammatory status and 
further investigation into macrophage infiltration, through immunohistochemical 
analysis ideally separating the M1/M2 phenotype, would be key in exploring this 
further. 
This model, in conclusion, produces a phenotype of mild hypertension and renal 
injury, which manifests primarily as perivascular fibrosis and vascular dysfunction. 
However, before this model is taken forward, it would be sensible to investigate further 
parameters, such as vascular dysfunction in resistance vessels, as well as the conduit 
vessels observed in this study. Other measurements, such as macrophage infiltration 
into vasculature and glomeruli, would also give valuable insights into the 
inflammatory status of kidneys of ANGII DOCA salt mice. 
Data collected thus far indicates that this is a valuable model of renal vascular 
pathophysiology, with current vascular dysfunction models not specifically targeting 
renal vessels. Not only this, but this model takes a multi-factorial approach without 
single causation, as is the case in early stages of human CKD. This model may be used 
for the investigation of biological agents in early CKD, particularly of those pathways 
contributing to vascular dysfunction evident at early stages of disease. Coupled with 
advances in early diagnosis of CKD through biomarker technology (Lopez-Giacoman 
& Madero 2015), this may aid in identifying novel drug targets for the treatment of 
CKD before fibrosis, renal dysfunction and significant renal damage are established. 
For our purposes, this model is used to represent early, vascular injury stages of CKD, 









Chapter 4: P2X7 expression and 
localisation in WT C57BL6 mouse renal 






















P2X7 has been extensively studied, primarily in cells associated with immunity and 
inflammation and in cells associated with pain (Lister et al. 2007). P2X7 has also been 
studied in the kidney and is upregulated upon a variety of renal insults at the whole 
kidney level (Vonend et al. 2004b; Kim et al. 2014) However, the expression and 
localisation of P2X7 specifically in the renal vasculature is less well known. 
In terms of renal vessels, P2X1 is known for its role in autoregulation (Inscho et al. 
2003). However, other P2X receptors aren’t so well characterised and with regards to 
P2X7, most studies have been carried out in the rat. In the rat, expression of P2X7 is 
present in mesangial cells, within the glomerulus, and within the endothelium of renal 
vessels (Inscho 2009; Turner et al. 2003; Lewis & Evans 2001). More recently in rats, 
the presence of P2X7 has been found in the endothelium of preglomerular vasculature 
and interlobar renal arteries, with upregulation and extension to the smooth muscle 
upon ANGII administration (Menzies et al. 2013; Menzies et al. 2015). P2X7 has also 
been identified in human endothelial cells (Yamamoto et al. 2000). However, the 
localisation of P2X7 in the mouse renal vasculature remains largely unexplored. 
In order to better understand the role of P2X7 in the renal vasculature of the mouse, it 
was necessary to undertake a thorough investigation into the localisation and 
expression of P2X7 in this location. An immunofluorescent method was optimised and 
validated via P2X1 staining. Further immunofluorescent experiments, co-localising 
P2X7 to various renal vascular cell types was undertaken, in both sham-operated 
control and ANGII DOCA salt mouse kidneys. Whole kidney western blot analysis 









4.2 Hypothesis and Aims 
I hypothesise that P2X7 will be present in the renal vasculature of mice, particularly 
in cell types that play a role in modulation of vascular tone; endothelial cells, vascular 
smooth muscle cells and pericytes. From review of the literature, I hypothesise that 
P2X7 will be present at higher levels in the ANGII DOCA salt mouse model of 
vascular renal injury. 
The aim of this research is to perform an in-depth localisation study using antibodies 
targeted to two different epitopes of P2X7, an intracellular and an extracellular epitope. 
P2X7 will be co-localised, via immunostaining and western blotting techniques, to 




















4.3.1 P2X7 expression and localisation in the C57BL6 mouse renal vasculature 
Two antibodies were used to detect P2X7; one which targets an intracellular epitope, 
P2X7(i) and one which targets an extracellular epitope, P2X7(e). Through comparing 
the epitope amino acid sequence to the five P2X7 isoforms reported in the mouse, it is 
evident that P2X7(e) antibody targets isoforms A, B, C and E and P2X7(i) antibody 








These antibodies were used to target P2X7 through western blotting and 
immunofluorescent techniques. In order to validate these techniques, they were first 
carried out using a well-documented antibody for P2X1, a member of the P2X family 
that has been extensively studied in the literature alongside endothelial cell marker 
CD31. Consistent with the literature, P2X1 was detectable in whole kidney 
homogenate through western blot (Figure 4.6) and was observed in the smooth muscle 
















Figure 4.1 - Antibodies used for 
P2X7 expressions and localisation 
studies 
(A) Two antibodies from Alomone 
Labs were used for 
immunofluorescence and western 
blotting, with each binding to a 
different set of P2X7 isoforms. (B) 
P2X7 isoforms represented by blue 
bars, show amino acid (aa) length, N 
and C terminals and points at which 
antibodies bind. P2X7(e) (left) targets 
an extracellular epitope, present on 
protein isotopes a, b, c, and e as 
indicated by green arrows. P2X7(i) 
(right; yellow) targets an intracellular 
epitope, present on protein isotopes a 











Using the same method with P2X7(e) and P2X7(i) antibodies, kidneys from C57BL6 
mice were immunostained for P2X7, alongside vascular markers for endothelium 
(CD31), vascular smooth muscle (αSMA) and pericytes (PDGFRβ). Depending on the 
P2X7 antibody used, different expression profiles were observed. 
Upon staining using the P2X7(e) antibody, P2X7 was present in renal tubules, 
glomerular mesangial cells and interstitium. Upon co-staining with vascular markers, 
P2X7(e) did not localise to the endothelium or smooth muscle of the vasculature. There 
was co-localisation to pericyte marker PDGFRβ at some focal points throughout the 
interstitium, but this was not a consistent observation across all PDGFRβ positive 
cells. 
Staining using the P2X7(i) antibody produced different results, with a strong co-
localisation of P2X7(i) and CD31 in renal vessel endothelium, both in interstitial 
vessels and glomerular capillaries. P2X7(i) also localised to PDGFRβ positive cells, 
particularly at perivascular areas. As with P2X7(e), P2X7(i) did not localise to the 
vascular smooth muscle. Neither antibody stained positive for P2X7 in p2xr7-/- kidney 
tissue, used as a negative control. 
 
P2X1 + Ag P2X1 + CD31 P2X1 + CD31 






Figure 4.2 - P2X1 expression in the smooth muscle of medium renal vessels and in 
the interstitium of glomeruli 
P2X1 staining (green) (A) pre-incubated with targeted antigen as a negative control, (B) 
alongside CD31 endothelial (red) staining in a medium renal vessel (V, highlighted 
with white dashed line) and (C) alongside CD31endothelial (red) staining in the 
glomerulus (G, highlighted with white dashed line), all with DAPI nuclear staining 
(blue). Co-localisation (yellow) was not observed. Scale bars = 25μm. All images were 

















































Figure 4.3 - P2X7 expression and vascular 
markers in the mouse renal vasculature, 
with two different P2X7 antibodies used. 
P2X7 staining (green) (A) in p2x7-/- kidney 
with DAPI nuclear stain. P2X7(i) staining 
(green) alongside (B) CD31 endothelial 
staining (red), (D) αSMA smooth muscle 
staining (red) and (F) PDGFRβ staining (red). 
P2X7(e) staining (green) alongside (C) CD31 
endothelial staining (red), (E) αSMA smooth 
muscle staining (red) and (G) PDGFRβ staining 
(red). Vessels (V) and glomeruli (G) are 
highlighted with white dashed lines. Co-
localisation (yellow) is highlighted with white 
arrows. Scale bars = 25μm. All images were 




4.3.2 P2X7 expression and localisation in the renal vasculature of the ANGII DOCA 
salt mouse 
The expression pattern observed in C57BL6 mouse kidneys was maintained when 
kidneys from sham operated and ANGII DOCA salt mice were stained using the same 
antibodies, co-stained with CD31. P2X7(e) once again localised to renal tubules, 
interstitium and glomerular mesangium and P2X7(i) to endothelium and perivascular 
areas (Figure 4.4).  
 
 
Figure 4.4 - P2X7 expression in the mouse renal vasculature of Sham and ANGII 
DOCA salt mice, with two different antibodies used. 
P2X7(i) staining (green) and CD31 staining (red) in (A) Sham and (B) ANGII DOCA 
salt mouse kidneys. P2X7(e) staining (green) and CD31 staining (red) in (C) Sham 
and (D) ANGII DOCA salt mouse kidneys. Vessels (V) and glomeruli (G) are 
highlighted with white dashed lines. Co-localisation (yellow) is highlighted with 
white arrows. DAPI nuclear staining is present in all images (blue). Scale bars = 






























Although the localisation of P2X7 did not change between Sham and ANGII DOCA 
salt mouse kidneys, the P2X7(i) staining at perivascular areas in ANGII DOCA salt 
mouse kidneys appeared more intense and exhibited a similar pattern to collagen 
deposition as detected through picrosirius red staining (Figure 4.5).  
 
Figure 4.5 - P2X7(i) and collagen staining in the interstitium of the ANGII 
DOCA salt mouse kidney.  
P2X7(i) immunofluorescent staining at (A) cortex and (B) perivascular areas. White 
arrows highlight positive P2X7 staining. Picrosirius red staining for collagen in 
fibrosis at (C) cortex and (D) perivascular area. Black arrows highlight positive 
collagen staining Scale bars = 25μm, images were taken at 40x objective. 
 
This increased intensity of P2X7(i) staining at perivascular areas was not, however, 
reflected at whole kidney level. When whole kidney homogenate was processed 
through Western blotting using the same antibodies, total levels of P2X1, P2X7(i) and 






Although canonical P2X7(i) and P2X7(e) at 60kDa was unchanged in ANGII DOCA 
salt mouse kidney homogenate, a smaller band detected on the same blot was 
upregulated in ANGII DOCA salt mice (Figure 4.7). Interestingly, this band, at 25kDa, 
was detectable using both P2X7(i) and P2X7(e) antibodies and does not correlate to 



























































Figure 4.6 - Western blot analysis of whole kidney homogenate to target 
canonical P2X7 with two different antibodies.  
(A) Total protein as measured via Coomassie Blue staining, used for normalisation 
and P2X1, P2X7(i) and P2X7(e) membranes as visualised by 
electrochemiluminescence (ECL). 50 = 50% protein control, 200 = 200% protein 
control. Quantification of membranes showed no significant difference in (B) 
P2X7(i) or (C)P2X7(e) expression in sham (blue; n=6) compared to ANGII DOCA 





Figure 4.7 - Western blot analysis of whole kidney homogenate to target all 
P2X7 bands with two different antibodies.  
Western blot membrane of (A) P2X7(i) antibody and (B) P2X7(e) antibody in whole 
kidney homogenate from Sham (blue lanes; n=6) and ANGII DOCA salt mice (red 
lanes; n=5). 70kDa band represents canonical form of P2X7. 25kDa band 
(highlighted with black arrow) represents unknown band. Semi-quantitative analysis 
of the 25kDa band suggest a significant increase in expression of this band in ANGII 

























P2X7 was also measured at the mRNA level, using primers targeted to a, b and c splice 
variants, which code for isoforms A, B and C. qPCR was carried out in whole kidney, 
aorta and spleen of Sham and ANGII DOCA salt mice. No change was seen in p2x7 
expression in whole kidney or in spleen, but a decrease in p2x7 was evident in the 
aortas of ANGII DOCA salt mouse aortas compared with those taken from Sham 










A B C 
Figure 4.8 - mRNA levels of p2x7 in Sham and ANGII DOCA salt mice.  
mRNA levels of p2x7 normalised to hprt housekeeper gene using primers that target 
protein coding mRNA for P2X7 isoforms A, B and C in (A) whole kidney, (B) spleen 
and (C) aorta from ANGII DOCA salt mice (red, , n=8) and sham (blue , n=8). 
Data are mean ± 95% CI, analysed by t-test.  
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4.3.3 Evidence for expression of P2X7 splice variants in mouse models of renal injury 
Given the observation of differential staining patterns of P2X7 using antibodies 
targeting different P2X7 isoforms and upregulation of an unknown 25kDa band 
targeted with P2X7 antibodies in ANGII DOCA salt mice, we decided to investigate 
p2xr7 splice variants in the ANGII DOCA salt mouse model and other models 
available to us. One such model was the reversal unilateral ureteral obstruction (R-
UUO) mouse model of renal fibrosis. RNAseq data for this model was available and 
thus mined for information on p2xr7 splice variants. Seven splice variants were 
identified, three of which were upregulated upon instigation of UUO (Figure 4.9). 
These expression levels did not drop in the week following reversal of this model 
through removal of the ureteric obstruction. These splice variants correlated to P2X7 
isoform A (splice variant 4), P2X7 isoform C (splice variant 5) and a non-coding piece 
of p2xr7 exon (splice variant 3). 
 
Figure 4.9 - P2X7 splice variant expression in a reversal unilateral ureteric 
obstruction (R-UUO) mouse model of  renal injury 
RNA sequencing data for whole kidney RNA from Sham operated mice (Sham; 
orange) UUO mice (purple: UUO), UUO mice plus 7 days reversal (green; 
UUO_R1W), UUO mice plus 14 day reversal (blue; UUO_R2W) and  UUO mice 
plus 28 day reversal (red; UUO_R4W), with each bar representing a different animal 
within the group. Splice variants are labeled 1 – 6 in the order that they were 
identified through the software. Splice variant 4 corresponds to canonical P2X7 
receptor isoform A. Splice variant 5 corresponds to alternative exon P2X7 receptor 
isoform C. Data collected and analysed by Carolynn Cairns and Dr. Bryan Conway, 
QMRI, Edinburgh. 
 
 Splice variant 1 Splice variant 2 Splice variant 3 
Splice variant 4 (Isoform A) Splice variant 5 (Isoform C) Splice variant 6 




Previous primers used for qPCR analysis of tissue targeted a range of p2xr7 splice 
variants, so primers were designed against the canonical receptor mRNA p2xr7a which 
appeared to be upregulated in a UUO model of renal injury (Figure 4.9). These primers 
were used to observe levels of this splice variant in the kidneys and aortas of both 
Sham and ANGII DOCA salt mice through end-point PCR. The levels of p2xr7a did 
not alter between Sham and ANGII DOCA salt mice in either the kidney or the aorta, 
but levels were variable between individual animals regardless of experimental 
grouping (Figure 4.10).  
 
 
Figure 4.10 – Expression of canonical p2x7a splice variant in kidney and aorta 
mRNA from Sham and ANGII DOCA salt mice 
End point PCR showing levels of p2x7a in kidney (above) and aorta (below) of 
either Sham (S1 – x) or ANGII DOCA salt (A1 – x) mice. Negative controls were 
without RNA (-RNA), without DNA polymerase (-DNA), without primers (-PRI) 
and p2x7-/- kidney tissue. Primers with nuclease free water (PRI + H2O) and nuclease 
free water (H2O) were ran to check purity and contamination. On the aorta gel 
(below), WT C57BL6 kidney cDNA (WT) and murine cortical collecting duct cell 









The aim of this study was to provide an in-depth localisation profile of P2X7 in the 
C57BL6 mouse kidney and to observe how this might change upon renal injury. 
Immunofluorescence and Western Blotting protocols were first performed with the use 
of P2X1, which localised to the expected areas, validating the method for continuation 
with P2X7 antibodies. Two antibodies were used, targeting different P2X7 splice 
variants, of which five are reported as present at the protein level. P2X7(i) targeted 
isoforms A and E, and P2X7(e) targeted isoforms A, B, C and E. Given the overlap in 
isoforms targeted by each antibody, it was surprising that the expression profiles were 
so different, with P2X7(i) localising primarily to the endothelium, glomerular 
mesangium and perivascular areas and P2X7(e) localising to the renal tubules and 
interstitium. It is possible that one of the isoforms targeted only by the P2X7(e) 
antibody (i.e. B or C) is present in the kidney at such high levels that expression of A 
and E in the CD31 positive endothelium and in PDGFRβ positive cells was 
undetectable in comparison. The positive staining of P2X7(i) is interesting as it 
localises to cells that play a role in the modulation of vascular tone, as hypothesised, 
providing supportive evidence that P2X7 plays a role in vasoactivity. 
P2X7(i) co-localised to PDGFRβ, as a marker of pericytes, however, this co-
localisation was not consistent throughout the kidney and occurred primarily at 
perivascular areas. PDGFRβ is not specific to pericytes and also target other cells such 
as fibroblasts and myofibroblasts, so further markers would be required to confirm the 
presence of P2X7 in pericytes, as seen in the literature (Am et al. 2013). It is, however, 
of interest that P2X7 may also be present in perivascular fibroblasts which play a role 
on collagen deposition (Greenhalgh et al. 2013). Data presented here show a similarity 
in P2X7(i) staining and collagen staining by picrosirius red, although co-localisation 
would be required to confirm this. If confirmed, this observation would be consistent 
with some findings in the literature whereby P2X7 has been linked to fibrosis (Gentile 
et al. 2015), such as the finding that P2X7 deficiency confers resistance to macrophage 
infiltration and collagen deposition in the murine UUO model of renal fibrosis 
(Gonçalves et al. 2006). 
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The antibodies used for immunostaining were also used for measuring P2X7 levels in 
Sham and ANGII DOCA salt mouse kidneys, although no change was seen using 
either antibody for the canonical P2X7 receptor at 60kDa. However, a smaller band 
detectable at 25kDa was upregulated in ANGII DOCA salt mice, although this does 
not correlate to the size of any of the known protein isoforms of P2X7. It is possible 
that this represents an as of yet unidentified isoform, as there are many more reported 
p2x7 splice variants in the mouse that have not been identified at the protein level 
(Bartlett et al. 2014b). However, it may also be a cleavage product released as a result 
of regulation of the receptor, for example. Amino acid sequencing of this band is 
required in order to give further insight into its origins. 
This finding, along with the contrasting localisation profiles observed using the 
different P2X7(i) and P2X7(e) antibodies, does suggest that there may be greater 
complexity of P2X7 and its splice variants than previously thought. In order to 
investigate this more closely, we also measured levels of P2X7 at the mRNA level.  
Firstly, this was carried out on kidney, spleen and aorta tissue from both Sham and 
ANGII DOCA salt mice using primers that targeted variants a, b and c. P2X7 is present 
at high levels in haemopoietic cells and so spleen tissue was used as a positive control. 
Levels of P2X7 were unchanged between groups in both the kidney and spleen, but 
were downregulated in the aorta. This is particularly interesting as we show that aortas 
from ANGII DOCA salt mice are dysfunctional when challenged with vasoconstrictor 
phenylephrine and vasodilator acetylcholine. However, these primers targeted three 
different splice variants and it was necessary to design primers against these individual 
splice variants to ascertain what specific renal area they are expressed in. 
In order to make a more informed choice of which splice variants to target, we explored 
data available us from the kidney RNA of mice from a UUO reversal study, which, of 
the seven identified as present, showed that three variants were upregulated upon 
injury in mice. These variants also remained highly expressed upon reversal of injury. 
One of these splice variants mapped to a non-protein coding short single exon, which 
could not therefore be detected through qPCR, but the remaining two mapped to 
p2xr7a and p2xr7c. Primers were therefore designed against these two variants, 
however; only the primers that targeted p2xr7a were successfully optimised, so data 
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is not available for p2xr7c at present. Expression of p2xr7a was unchanged between 
Sham and ANGII DOCA salt mice, both in kidneys and in aortas. What was more 
striking in this observation was the expression between individual mice, which was 
highly variable regardless of grouping. It may be that p2xr7a is variably expressed and 
there are shifts or important roles of other splice variants, such as p2xr7c in the kidney 
and aorta of WT mice, as well as those challenged with renal injury. Successful 
optimisation of primers targeting these variants is required to further investigate their 
expression levels and potential roles in the murine kidney. 
In conclusion, this study provides a comprehensive overview of the expression of 
P2X7 in the mouse renal vascular and supports the hypothesis that P2X7 plays a role 
in modulation of vascular tone. It also provides emerging evidence for the role of P2X7 
splice variants as a vasoactive component in the physiological function of the mouse 
kidney, with a noted change in expression in vessels upon renal injury through ANGII 











































Chapter 5: The role of P2X7 in 























P2X7 overexpression and abnormal activity has been linked to renal disease in both 
rodents and humans (Vonend et al. 2004b; Ji et al.2012a; Ji et al. 2012b; Gonçalves et 
al. 2006). Most studies suggested that this is due to an inflammatory role of receptor 
activation and in a wider context, P2X7 antagonists were developed for deployment in 
conditions of chronic inflammation. However, clinical trials to use P2X7 antagonists 
in treatment of inflammatory disease, such as rheumatoid arthritis, have been 
unsuccessful (Stock et al. 2012; Keystone et al. 2012). More recent studies reflect on 
the role of P2X7 in the vasculature, suggesting that it may contribute to vasoactivity 
and influence the interaction between the vascular endothelium and immune cells. For 
example, in rat retina, P2X7 activation causes constriction of capillaries (Kawamura 
et al. 2003). In a mouse model of septic encephalopathy,  P2X7 is a vital component 
in the recruitment of leukocytes in to the cerebral endothelium (Wang et al. 2015) and 
is  also implicated in the vascular dysfunction induced by LPS (Chiao et al. 2008; 
Chiao et al. 2013). In a renal context, acute blockade of P2X7 reduces blood pressure 
and increases renal blood flow in a rat model of ANGII-induced kidney injury 
(Menzies et al. 2015) and restores glomerular inulin space, an indicator of GFR, in a 
rat model of diabetic nephropathy (Kreft et al. 2015).  
In sum, these studies suggest that P2X7 activation exerts a tonic vasoconstriction, 
particularly in renal disease, supporting the hypothesis that its overexpression could 
result in reduced renal blood flow and contribute to a renal disease phenotype. 
However, at the start of this work, direct observation of the effect of specific P2X7 
agonists and antagonists on vascular tone was lacking. In this chapter, I therefore 
investigated the effect of the P2X7-selective agonist BzATP and P2X7-specifc 
antagonist AZ11657312 on vasoconstriction in mouse aorta from both sham and 
ANGII DOCA salt mice. In vivo, the effect of the P2X7 antagonist on renal blood flow 







5.2 Hypothesis  
I hypothesise that activation of P2X7 will induce a vasoconstriction of the isolated 
mouse aorta, exaggerated in ANGII DOCA salt animals. I hypothesise that antagonism 
of P2X7 will reduce this constrictive effect which will lead to a reduction in blood 
























5.3.1 P2X7 agonism results in an endothelial independent vasoconstriction in mouse 
aortas 
Wire-myography was performed on mouse aorta dissected from untreated C57BL6 
mice. Measurements were made in both endothelium-intact and endothelium- denuded 
states. Removal of the endothelium did not significantly alter the response to 
phenylephrine (PE) (Figure 5.1A). However, the PE curve for denuded vessels was 
shifted slightly to the left and exhibited a slightly higher EC50 than was observed for 
intact aorta. This is to be expected as in intact vessels, PE activates α1-adrenoceptor 
present on both smooth muscle cells and endothelial cells. These receptors mediate a 
strong vasoconstriction via smooth muscle cells through increasing intracellular 
calcium but mediate a moderate vasodilation via endothelial cells through increasing 
nitric oxide (NO) production. The overall effect is that endothelial deficient vessels 
are slightly more responsive to phenylephrine as they lack the opposing vasodilatory 
effect mediated by endothelial cells. 
Denuded aortas were significantly less responsive to the endothelium-dependent 
vasodilator acetylcholine (Ach; Figure 5.1B). However, the response of intact aortas 
was still relatively low in intact vessels compared to intact EC50 baseline, retaining 
approximately 50% of PE-induced constriction at the highest concentration of Ach 
(Table 5.1).  
BzATP, a P2X7-selective agonist, induced a vasoconstriction in both intact and 
denuded vessels (Figure 5.1C) but there was no significant difference in the 










Figure 5.1 - Dose response curves of intact and denuded aortas from C57BL6 
male mice to phenylephrine, acetylcholine, BzATP and KPSS. Response of 
denuded aortas (red, , n=6) and intact aortas (blue , n=6) from C57BL6 mice to (A) 
vasoconstrictor phenylephrine (PE), displayed as percentage force (mN) of maximum 
force (mN) as determined by (125mM) KCl response, vasodilator (B) acetylcholine 
(Ach), displayed as percentage force (mN) of force (mN) at EC50 PE and (C) BzATP 
displayed as percentage force (mN) of maximum force (mN) as determined by 
(125mM) KCl response. Data points are mean ± SD with non-linear regression. All 
data are analysed by two-way ANOVA. (D) Response of same vessels to 125mM 
KPSS displayed as force in millinewtons (mN). Data points are mean ± 95%C.I. Data 







Table 5.1 - EC50 and maximal responses of vessels to vasoactive pharmacological 
agents. EC50 expressed as – log [concentration in M] and maximal response of intact 
and denuded aortas from C57BL6 mice to phenylephrine (PE; 1.0E-6M), acetylcholine 
(Ach; 1.0E-5M), BzATP (50μM) and 125mM KCl. PE and BzATP responses are 
expressed as %KCl response, Ach responses are expressed as 100 – % relaxation, KCl 





































Intact 6.82 92.04±15.7 49.95±10.5 31.85±7.1 3.47±0.7 
Denuded 7.26 102.82±5.1 25.15±5.6 50.42±10.1 2.90±0.5 
90 
 
5.3.2 P2X7 antagonism has no effect on renal function in either Sham or ANGII DOCA 
salt animals 
In order to observe the effect of P2X7 antagonism on mean arterial blood pressure 
(MABP), renal blood flow (RBF) and glomerular filtration rate (GFR) (Figure 5.3), 
amongst other renal function parameters (Figure 5.3, Table 5.) in a model of renal 
vascular injury, P2X7 specific antagonist AZ1165712 was administered to sham and 
ANGII DOCA salt mice at a dose of 12mg/kg under anaesthetic during a renal 
clearance experiment. Previously, differences had been observed between Sham and 
ANGII DOCA salt animals, before vehicle or AZ11657312 administration (Chapter 
3). In this study, focus was on changes in renal function within each group upon vehicle 
or AZ11657312 administration. However, no significant differences in renal function 
were observed between vehicle treated and AZ11657312 treated animals in either the 
Sham or ANGII DOCA salt group, with the exception of fractional excretion of 
potassium, which was significantly downregulated upon administration of 


















Figure 5.3 - Blood pressure, glomerular filtration rate, renal blood flow and renal 
vascular resistance in Sham and ANGII DOCA salt mice, treated with either 
vehicle or P2X7 antagonist AZ11657312. (A) Systolic blood pressure (SBP), (B) 
glomerular filtration rate (GFR), (C) renal blood flow (RBF) and (D) renal vascular 
resistance (RVR) in vehicle treated Sham mice (n=2), AZ11657312 (12mg/kg) treated 
Sham mice (n=3), vehicle treated ANGII DOCA salt mice (n=2) and AZ11657312 













Figure 5.4 - Sodium and potassium handling in Sham and ANGII DOCA salt 
mice, treated with either vehicle or P2X7 antagonist AZ11657312. (A) Sodium 
excretion, (B) potassium excretion, (C) fractional sodium excretion, (D) fractional 
potassium excretion, (E) urine flow rate and (F) haematocrit in vehicle treated Sham 
mice (n=2), AZ11657312 (12mg/kg) treated Sham mice (n=3), vehicle treated ANGII 
DOCA salt mice (n=2) and AZ11657312 (12mg/kg) treated ANGII DOCA salt mice 









Table 5.2 - Blood pressure and plasma concentrations of sodium and potassium 
in Sham and ANGII DOCA salt mice treated with either vehicle or AZ11657312. 
Data are mean ± S.E.M. Data analysis by t-test. No significant changes were observed 
between vehicle or P2X7 antagonist treated mice in either Sham or ANGIIDOCA salt 
groups. 























4.0±0.0 4.0±0.0 1.5* 1.5* 
* All plasma potassium measurements made in ANGII DOCA salt mice were below the 
lower limit of detection of equipment used. For the purpose of further calculations, the 






5.3.3 Testing the efficacy of AZ11657312 in BMDMs shows that AZ11657312 inhibits 
P2X7 by ~15% 
AZ11657312 was originally used due to previously successful results carried out in 
rats within my laboratory group. However, AZ11657312 did not have the hypothesised 
effect on BP and RBF in a small group of animals. Before increasing the study size, I 
opted to assess whether the compound was an effective antagonist of mouse P2X7. An 
experiment was performed to test AZ11657312 alongside the well-documented, 
commercially available compound A438079 (Tocris). Murine bone marrow derived 
macrophages (BMDMs) were treated with lipopolysaccharide (LPS) and adenosine 
triphosphate (ATP) to elicit production of IL-1B, which has previously been shown to 
be a downstream effect of P2X7 activation. Other groups of cells were then treated for 
either 1 hour or 2 hours with AZ11657312 (10μM) or A438079 (10μM).  
 
Figure 5.5 - IL1β production by murine bone marrow derived macrophages 
(BMDMs) in response to LPS and ATP activation when pre-incubated with 
P2X7 antagonists. IL-1B production in murine BMDMs in response to 
lipopolysaccharide (LPS) and ATP after pre-incubation for 1 hour (1h) or 2 hours 
(2h) with P2X7 antagonist AZ11657312 (10μM; blue bars) or P2X7 antagonist 
A438079 (10μM; red bars). All IL1β data shown as a percentage of IL1β 
concentration in control LPS and ATP treated cells. Data are mean ± S.D, n=3 for 
all groups, data analysed by one-way ANOVA, *p<0.05, ***p,0.005, 




The resultant IL-1B production was then measured and compared to control LPS + 
ATP treated cells with no antagonism. Results showed that treatment of BMDMs with 
AZ11657312 only slightly inhibited IL1B production by ~15% whereas treatment with 
A438079 resulted in a ~85% decrease in IL1B production, suggesting that the latter is 
a more effective P2X7 antagonist in murine BMDMs. 
5.3.4 P2X7 antagonism results in an increase in vasoconstriction in ANGII DOCA salt 
mouse aortas, but not in Sham aortas 
Returning to wire-myography, the role of P2X7 in control of vascular tone was 
assessed in isolate mouse aorta, incubating vessels with either a P2X7 antagonist 
A438079 (10μM) or vehicle (matched volume ddH2O), prior to stimulation with the 
P2X7 agonist BzATP (50μM). Vessels were also subject to a dose response of PE, Ach 
and SNP to check vessel health independently of P2X7 agonism/antagonism. This 
study was performed in Sham and ANGII DOCA salt mice over two separate 
experimental runs, initially with n= 4 and 5 per group and then with n= 7 and 8.). The 
results obtained from these two rounds of experiments were quantitatively distinct and 
therefore the data are presented as two separate cohorts.  
Results showed that, over both experiments, response to PE and Ach was increased in 
ANGII DOCA salt aortas compared to Sham and there was no change in SNP response 
as previously discussed (Chapter 3). Similarly, KPSS responses did not differ between 
groups or experimental repeats.  
However, response to BzATP differed between groups and this effect changed upon 
repetition of the experiment. In the first experiment, BzATP response was not 
significantly different between Sham and ANGII DOCA salt mouse aortas. Upon 
treatment with A438079, vasoconstriction was significantly decreased in Sham aortas, 
but significantly increased in ANGII DOCA salt aortas, when compared to vehicle 
treated controls. 
In the repeated experiment, with increased group sizes, the constrictive response to 
BzATP was higher in ANGII DOCA salt aortas compared to Sham. Upon treatment 
with A438079, vasoconstriction was unchanged in Sham aortas and, again, 
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significantly increased in ANGII DOCA salt aortas, when compared to vehicle treated 
controls and the variation in this group was larger than that of the others. 
The consistent finding taken from these results is that P2X7 antagonism leads to an 































Figure 5.6 - First Experiment: Response of intact aortas from Sham and ANGII 
DOCA salt mice to phenylephrine, acetylcholine, sodium nitroprusside, BzATP 
and KPSS in the presence of a vehicle or A438079 P2X7 antagonist. Response of 
aortas from ANGII DOCA salt mice (red, n=10) and Sham mice (blue, n=8) to (A) 
vasoconstrictor phenylephrine (PE), displayed as percentage force (mN) of maximum 
force (mN) as determined by (125mM) KCl response, (B) vasodilator acetylcholine 
(Ach), displayed as percentage force (mN) of force (mN) at EC50 PE, (C) vasodilator 
sodium nitroprusside (SNP), displayed as percentage force (mN) of force (mN) at 
EC50 PE, (D) 125mM KPSS displayed as force in millinewtons (mN) and (E) BzATP 
(50μM) displayed as percentage force (mN) of maximum force (mN) as determined 
by (125mM) KCl response. For KPSS and BzATP response, Sham and ANGII DOCA 
salt mice were further split into 2 separate groups; vehicle treated (ddH2O; n=4 - 5) or 
P2X7 antagonist A438079 treated (10μM; n=4 - 5). For PE, Ach and SNP response, 
data points are mean ± SD with non-linear regression, analysed by two-way ANOVA, 
*p<0.05, **p<0.01, ***p<0.0005, ***p<0.0001. For KPSS and BzATP response, data 
















Table 5.3 - First Experiment: EC50 and maximal responses of vessels to vasoactive 
pharmacological agents. EC50 expressed as – log [concentration in M] and maximal 
response of aortas from Sham and ANGII DOCA salt mice in the presence of vehicle 
(ddH2O) or P2X7 antagonist A438079 (10μM) to phenylephrine (PE; 1.0E-6M), 
acetylcholine (Ach; 1.0E-5M), sodium nitroprusside (SNP; 1.0E-5M), BzATP (50μM) 
and 125mM KCl. PE and BzATP responses are expressed as %KCl response, Ach and 
SNP responses are expressed as 100 – % relaxation, KCl responses are expressed in 
millinewtons (mN). Data are mean±S.E.M. 
Group 



























































































Figure 5.7 - Repeated Experiment: Response of intact aortas from Sham and 
ANGII DOCA salt mice to phenylephrine, acetylcholine, sodium nitroprusside, 
BzATP and KPSS in the presence of a vehicle or A438079 P2X7 antagonist. 
Response of aortas from ANGII DOCA salt mice (red, n=15) and Shame mice (blue, 
n=15) to (A) vasoconstrictor phenylephrine (PE), displayed as percentage force (mN) 
of maximum force (mN) as determined by (125mM) KCl response, (B) vasodilator 
acetylcholine (Ach), displayed as percentage force (mN) of force (mN) at EC50 PE, 
(C) vasodilator sodium nitroprusside (SNP), displayed as percentage force (mN) of 
force (mN) at EC50 PE, (D) 125mM KPSS displayed as force in millinewtons (mN) 
and (E) BzATP (50μM) displayed as percentage force (mN) of maximum force (mN) 
as determined by (125mM) KCl response. For KPSS and BzATP response, Sham and 
ANGII DOCA salt mice were further split into 2 separate groups; vehicle treated 
(ddH2O; n= 7 - 8) or P2X7 antagonist A438079 treated (10μM; n=7 - 8). For PE, Ach 
and SNP response, data points are mean ± SD with non-linear regression, analysed by 
two-way ANOVA, *p<0.05, **p<0.01, ***p<0.0005, ***p<0.0001. For KPSS and 
BzATP response, data points are mean ± 95%C.I, analysed by t-test. For KPSS 


















Table 5.4 - Repeated Experiment: EC50 and maximal responses of vessels to 
vasoactive pharmacological agents. EC50 expressed as – log [concentration in M] 
and maximal response of aortas from Sham and ANGII DOCA salt mice in the 
presence of vehicle (ddH2O) or P2X7 antagonist A438079 (10μM) to phenylephrine 
(PE; 1.0E-6M), acetylcholine (Ach; 1.0E-5M), sodium nitroprusside (SNP; 1.0E-5M), 
BzATP (50μM) and 125mM KCl. PE and BzATP responses are expressed as %KCl 
response, Ach and SNP responses are expressed as 100 – % relaxation, KCl responses 
are expressed in millinewtons (mN). Data are mean±S.E.M. 
Group 





























































As predicted, P2X7 specific agonism through BzATP administration has a 
vasoconstrictive effect on mouse aorta, an effect that appears to be independent of the 
presence of the endothelium. The endothelial effect is somewhat unexpected as 
expression data (Chapter 4) shows that P2X7 expression is largely located on the 
endothelium, however, this data was focussed on the renal vasculature rather than the 
aorta. Staining for P2X7 in the aorta was attempted, but unsuccessful, so this would 
need to be carried out before making any conclusions.  
Additionally, the response of intact aortas to endothelium dependent acetylcholine, 
although greater than denuded vessels as expected, was not as great as previous reports 
and baseline data would indicate, with dilatory response reaching around 50%, rather 
than up to 100%. This could be due to damage of vessels or a defect in the drug and 
repetition of this experiment with a more reliable batch of acetylcholine could explain 
this phenomenon. 
BzATP also binds P2X1, as well as P2X7 so receptor cross over and compensation 
adds complexity to the results. An agonist specific to P2X7 only would be needed to 
investigate this with more accuracy, but such a compound is not currently 
commercially available. Renal clearance studies show no effect of P2X7 antagonism 
on renal function with the use of AZ11657312 in either Sham or ANGII DOCA salt, 
except for resulting in a slight decrease in fractional potassium excretion in Sham mice. 
This was unexpected as previous renal clearance studies in rats had achieved 
significant, dose dependant decrease in blood pressure and increase in renal blood flow 
upon administration of the same compound at a lower dosage (Menzies et al. 2015). 
The group sizes used in our mouse experiment were small and so the negative results 
could be a result of a lack of power, however, it may also be a species effect. Although 
canonical versions of the P2X7 receptor in mice and rats share 84% sequence 
homology, small changes in amino acid sequence can induce differential responses to 
P2X7 agonists (Young et al. 2007). Differential response to other P2X7 antagonists 
has also been reported between species (Michel et al. 2009) and as such, this may be 
the case with AZ11657312. 
105 
 
Another level of complexity is added when the different splice variants of P2X7 are 
considered, of which there are 2 protein isoforms observed in rats, 8 in mice and 10 in 
humans, all of which may present different responses to a single P2X7 agonist or 
antagonist. 
Because no effect was seen in the renal clearance experiment using AZ11657312, a 
different compound was considered for further P2X7 antagonism studies - A438079, 
which is commercially available from Tocris and has been documented in previous 
studies (Ponnusamy et al. 2011; Wang et al. 2015; Kreft et al. 2016; Sathanoori et al. 
2015; Menzies et al. 2017; Yan et al. 2015). 
In order to observe the effect of AZ11657312 and A438079 on mouse P2X7 receptors, 
a cell study was carried out in which cells were treated with LPS and ATP, plus 
incubation with either antagonist. The resultant IL-1B production, a downstream effect 
of P2X7 activation, was then measured. Results showed that A438079 was much more 
effective in reduced IL-1B production than AZ11657312 and so this was the P2X7 
antagonist carried forward for future studies. 
Myography studies into the effect of P2X7 antagonism in Sham and ANGII DOCA 
salt mice were carried out in order to observe how the role of P2X7 changes under 
pathophysiological conditions, in this case a murine model of early renal vascular 
injury (outlined in Chapter 3). This study was carried out initially with group sizes of 
4 - 5, upon which no change in response was seen between Sham and ANGII DOCA 
salt aortas. In this study, P2X7 antagonism with A438079 resulted in a significant 
decrease in BzATP-induced vasoconstriction in Sham aortas, but a significant increase 
in BzATP-induced vasoconstriction in ANGII DOCA salt aortas. This observed effect 
in ANGII DOCA salt aortas was unexpected, as we hypothesised that P2X7 is 
vasoconstrictive and its antagonism would lead to a reduced constriction in response 
to BzATP. 
We therefore repeated this experiment with larger group sizes of 7 - 8. In both 
experiments, response of Sham and ANGII DOCA salt aortas to PE, Ach and SNP was 
measured independently from P2X7 agonism and antagonism. In both experiments, 
hyper-reactivity of aortas to PE and Ach was seen in ANGII DOCA salt mice 
compared to Sham and no difference was seen between groups on response to SNP. 
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However, in the repeated experiment, a different response was observed to BzATP - 
firstly, constriction of ANGII DOCA salt mouse aortas in response to BzATP was 
significantly higher than that of Sham mouse aortas, where no difference was seen in 
the first experiment. Also, although a decrease in constriction was seen upon P2X7 
antagonism in Sham mice in the first experiment, no significant difference was 
observed in the repeated experiment, when group sizes were increased. However, 
consistently with the first set of data, the repeated experiment showed that P2X7 
antagonism in ANGII DOCA salt aortas resulted in a significantly increased 
constriction in response to BzATP. 
Power calculations were performed on data from the first experiment in order to 
generate group sizes large enough to unearth possible statistical significance upon 
repetition of the experiment, making the results from the repeated experiment more 
reliable. According to the repeated experiment, ANGII DOCA salt mouse aortas 
responded much more strongly to BzATP compared to Sham. This may be due to an 
upregulation of the P2X7 receptor, which, as discussed in Chapter 4, is not present in 
the canonical form, but may be present in other splice variants of P2X7. A change in 
P2X7 splice variant expression profile in ANGII DOCA salt mice compared to Sham 
mice may also explain why P2X7 antagonism had no effect in Sham mice but induced 
a stronger constriction in ANGII DOCA salt mice. To elucidate this, further 
investigation into the expression of P2X7 splice variants in this model would need to 
be undertaken (as discussed in Chapter 4). This would also give insight into potential 
differences in affinity of P2X7 agonists and antagonists for different splice variants 
isoforms, as discussed earlier. 
However, it may not be cross specificity between P2X7 isoforms that mediate the 
effect seen but cross specificity between purinergic receptors in general. Although 
A438079 is a specific antagonist of P2X7, the P2X7 agonist BzATP can also bind to 
P2X1. P2X1 is well documented vasoconstrictor present in the smooth muscle of 
vessels, including renal vessels and the aorta (Lewis & Evans 2001; Inscho et al. 2011). 
Upon P2X7 antagonism in ANGII DOCA salt aortas, it may be that BzATP binds more 
strongly with P2X1, leading to an overall increase in vasoconstriction, which masks 
the effect of P2X7. In order to pick apart this cross over, specific P2X1 antagonists 
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would need to be incorporated into this experiment, which would be of great interest 
in further studies. 
Collectively, this data does show that P2X7 has a vasoconstrictive effect in the 
C57BL6 mouse aorta, which is potentially reversed under a murine model of renal 
vascular injury. However, elimination of contribution of other purinergic receptors in 
these experiments, such as P2X1, is needed to be sure of this. Additionally, the 
complexity of receptor cross talk and the presence of P2X7 splice isoforms, which 
differ between species, needs to be understood more clearly before the role of P2X7 

































































Increased P2X7 expression has been implicated in a plethora of diseases, including 
inflammatory conditions, pain pathways and renal injury (Bartlett et al. 2014). In 
experimental models of renal injury or disease, such as inflammatory (Ji et al. 2012a; 
Ji et al. 2012b), pro-fibrotic (Goncalves et al. 2006) and vascular (Menzies et al. 2015), 
P2X7 knockout or antagonism has been beneficial. Nevertheless, clinical trials to use 
P2X7 antagonists as a therapeutic for inflammatory disease such as rheumatoid 
arthritis have been unsuccessful (Keystone et al. 2012; Stock et al. 2012), suggesting 
a persistent knowledge gap concerning the fundamental biology of P2X7 in health and 
disease. Closing this gap, particularly in the context of chronic kidney disease (CKD) 
will make repurposing of P2X7 antagonists into renal therapeutics ever more appealing 
(Menzies et al. 2017). However, the mechanistic underlying of the role of P2X7 in the 
kidney is still not well understood, due to historic lack of research into P2X7 in this 
organ and because of the difficulty of mimicking all the human pathophysiological 
elements of CKD in a rodent model.  
 
The primary aim of this thesis was to investigate the role and expression of P2X7 in 
C57BL6 mice, using a recently described, slowly progressing model of CKD. The 
intention of my research was to contribute to a deeper understanding of P2X7 function, 
supporting investigation into P2X7 antagonists as renal therapeutic targets. I first 
characterised a new model for investigating CKD in C57BL6 mice by chronic 
treatment with combinatorial ANGII, DOCA and salt.  As described first by Kirchhoff 
(Kirchhoff et al. 2009) this multi-induction approach produces progressive renal 
injury. In my hands, mice developed mild hypertension and renal injury manifesting 
primarily as perivascular fibrosis and vascular dysfunction. Localisation and 
functional studies into this model and in control mice have provided a comprehensive 
overview of the expression of P2X7 in the mouse renal vascular and supports my 
hypothesis that P2X7 plays a role in modulation of vascular function. P2X7 was found 
in endothelial cells and in PDGFRβ positive cells. P2X7 expression was upregulated 
in ANGII DOCA salt mice, as was the PDGFRβ cell population. Overall, renal fibrosis 
was not elevated but the extent of collagen deposition around the macrovasculature- 
perivascular fibrosis- was much higher in the experimental group. In functional 
studies, aorta from ANGII DOCA salt mice were hyper-responsive to vasoconstrictor 
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phenylephrine, an effect which was amplified upon P2X7 antagonism. My data also 
demonstrates the complexity of the splice variation of p2xr7, highlighting the 
importance of variant genotype in the context of using P2X7 antagonists in clinical 
trials. 
 
The findings surrounding the characterisation of the ANGII DOCA salt model are 
discussed in detail in chapter 3. Here, I highlight the observation that the population 
PDGFRβ positive cells in ANGII DOCA salt kidneys was much higher than that in 
Sham mice, and that perivascular fibrosis, though not interstitial fibrosis, was 
significantly higher in the kidneys of ANGII DOCA mice. Not only this, but the 
vascular function of aortas from ANGII DOCA salt mice was significantly difference 
to those taken from Sham mice.  
These outcomes from my PhD research have been discussed in early chapters. Here I 
highlight aspects that I consider important and briefly discuss the perspectives of my 
research.  
6.1 Localisation and expression of P2X7 in the mouse kidney 
Investigation of P2X7 in mouse kidneys showed that P2X7 can be localised to CD31 
positive endothelial cells, although not the αSMA expressing smooth muscle layer of 
renal vessels. The presence of P2X7 in endothelial cells is well documented 
(Yamamoto et al. 2000; Lewis & Norman 2004; Menzies et al. 2013). Some studies 
suggest that P2X7 is present in the smooth muscle of renal vessels, particularly under 
injury models (Lewis & Norman 2004; Menzies et al. 2013), but my data does not 
support this. This discrepancy could potentially reflect the variability of target binding 
sites epitopes with different P2X7 antibodies, which may ‘hit or miss’ different splice 
variant products of the p2xr7 gene. This complication of P2X7 was evident upon 
measuring P2X7 expression levels in ANGII DOCA salt mice. P2X7 was increased in 
ANGII DOCA salt kidneys (determined by western blot, capturing 4 splice variants 
protein products, including the canonical form), increased in ANGII DOCA salt aorta 
(determined by qPCR, capturing 3 splice variants including the canonical form) and 
increased in the kidneys of UUO mice (determined by RNAseq, capturing 3 splice 
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variants of p2x7 including the canonical form) compared to Sham. The complexity of 
this splice variation is discussed in more detail later in this chapter. 
 
Perhaps most interestingly, my localisation data shows that P2X7 co-localises to 
PDGFRβ positive cells in C57BL6 mouse kidneys. PDGFRβ is a marker that  covers 
many types of cells, one of which is perivascular cells such as pericytes, which have 
roles in the kidney as modulators of vascular tone and differentiation into 
mesenchymal myofibroblasts which play roles in collagen deposition in the process of 
renal fibrosis (Lebleu et al. 2014). The literature on P2X7 and its role within pericytes 
is not extensive, however some studies have observed some links. P2X7 has been 
implicated in vascular control of the rat retina, via pericytes (Sugiyama 2014; 
Kawamura et al. 2003) and has even been identified within human pericyte cultures . 
It is of particular interest that the ANGII DOCA salt model exhibits vascular 
dysfunction, increased pericyte populations and perivascular fibrosis in conjunction 
with P2X7 expression, as this feeds into research theories of the progression of 
tubulointerstitial fibrosis. 
6.2 Pericytes and perivascular fibrosis 
Pericytes are found throughout the body, wrapped around capillaries, mediating vital 
functions such as angiogenesis and vasoconstriction. They are of particular interest in 
the kidney, where they can be found in a specialized form of mesangial cells within 
the glomerulus, and renin expressing pericytes at the afferent arteriole, thus 
contributing to systemic blood pressure. In these locations, they can also differentiate 
into pro-fibrotic mesenchymal cells, potentially initiating the process of organ fibrosis 
(Shaw et al. 2018). 
 
Evidence does exist to support the theory of perivascular fibrosis as the first step 
towards tubulointerstitial fibrosis and organ scarring. In an ANGII rat model of renal 
injury, Faulkner et al. suggested that the initiation of fibrosis observed lay in 
perivascular myofibroblasts, rather than in tubular epithelial cells (Faulkner et al. 
2005). In a UUO + IRI mouse model of fibrosis, lineage tracing techniques could not 
113 
 
ascribe the myofibroblasts mediating the injury to tubular epithelial origin 
(Humphreys et al. 2010). These studies highlight the potential significance of 
perivascular cells such as pericytes in the context of renal injury, but this concept is 
still not well understood and further exploration of this process is required. 
Establishing the role of P2X7 in this process may not only provide better 
understanding of how P2X7 contributes to renal disease, but may also shed further 
light on the importance of pericytes and perivascular fibrosis as the initiating step in 
renal fibrosis.  
 
My data shows co-localisation of P2X7 and PDGFRβ in C57BL6, but I was not able 
to achieve successful co-staining in my ANGII DOCA salt model, due to antibody 
batch variations and hence the requirement to re-optimise my immunostaining method 
for each batch, which I did not have sufficient time to complete. What my data from 
the ANGII DOCA salt model does show is that both whole kidney P2X7 expression 
and presence of PDGFRβ positive renal populations were increased. My ANGII 
DOCA salt model shows increased perivascular fibrosis, through staining of collagen 
in a pattern mimicking P2X7 staining in ANGII DOCA salt kidneys. However, again 
due to protocol and time limitations, I was unable to optimise a method for co-staining 
of P2X7 and collagen. These data show potential for a locational, if not functional, 
overlap between P2X7 and pericyte mediated perivascular fibrosis – however the data 
do not provide evidence for this. Successful co-staining for P2X7 and collagen, and 
P2X7 and PDGFRβ (if not extra, more specific markers for pericytes, as PDGFRβ 
alone targets multiple cell types) would be required to provide evidence to support this 
direction of research. 
 
6.3 p2xr7 splice variation 
My investigation into the role of murine P2X7 in CKD highlights the complexity of 
splice variation within p2xr7, which hasn’t previously gone unnoticed in the field. The 
canonical form of P2X7 is preferentially expressed in macrophages (Surprenant et al. 
1996), whereas the P2X7k isoform variant is preferentially expressed on T-cells, 
114 
 
exhibiting an 8-fold higher sensitivity to P2X7 agonists (Nicke et al. 2009). P2X7k is 
implicated in pore formation, whereas the P2X713C, the mRNA of which has an 
alternative exon 13, demonstrates no pore formation at all and is expressed most 
notably in the brain, salivary glands and lung (Masin et al. 2012). Another P2X7 
isoform with an alternative exon 13 transcript is P2X713B, which also doesn’t 
demonstrate pore formation, and is found in brain and salivary glands, as well as the 
spleen (Masin et al. 2012). Perhaps most interestingly, p2xr7-/- mice produced by 
GlaxoSmithKline (GSK) and Pfizer show incomplete knock out of all P2X7 isoforms. 
Although both lines knock out the canonical form of P2X7, the GSK line still exhibits 
the P2X7k variant and the Pfizer line still exhibits P2X713B and P2X713B (Bartlett 
et al. 2014). The complexity of splice isoforms observed in rodents has also been 
identified to a lesser degree in human cells and tissue (Cheewatrakoolpong et al. 2005). 
These observations highlight the variability in P2X7 isoforms expression and function, 
as well as the importance of considering these isoform profiles in a research setting. 
 
The data shown in this thesis supports the literature in that different expression profiles 
of p2xr7 were observed depending on detection antibodies used, the renal injury 
induced and the tissue in which p2xr7 levels were measured. Immunofluorescent 
experiments using sham and ANGII DOCA salt mouse kidneys resulted in differential 
staining depending on the P2X7 antibody used, likely because they target a different 
subset of P2X7 splice variant products within the same tissue. I have shown data which 
portrays p2xr7 splice variant dependant expression in a model of UUO, where some 
variants are upregulated, and others not. I have observed an upregulation of p2xr7 in 
whole kidney RNA from ANGII DOCA salt mice compared to Sham, but a 
downregulation in aorta RNA using the same p2xr7 specific primers, protocol and 
cohort tissue. 
 
P2X7 isoforms have been described to self-regulate expression (Masin et al. 2012). 
This is interesting, as RNAseq analysis of UUO kidney mRNA shows an upregulation 
of 4 splice variants, one of which represents a non-coding protein variant. Further 
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investigation of this splice variant would be interesting, as self-regulation of splice 
variation is often mediated through non-coding RNA (Tazi et al. 2009). 
 
The observations made here, alongside the available literature are not only important 
for awareness of off target effects in research, but may also represent the initial switch 
that contributes to disease states. Splice variation is vital in regulating expression of 
protein coding genes, however it is also linked to disease states (Tazi et al. 2009). It is 
possible that the difference in splice variant isoforms of P2X7 seen in the ANGII 
DOCA salt model are a result of their intrinsic link to the disease state and P2X7 
isoform profiles are completely different in injury than in healthy kidneys, although 
much more research is needed to explore this theory. 
 
The key concept that is gained from these data is that p2xr7 has a complex 
transcriptional regulation and profile that is likely dependant on the specific cell 
population (Bartlett et al. 2014). Thus, bulk transcriptomics are unlikely to be very 
informative and instead the potential to do RNAseq on populations, or even on 
individual cells, is likely to lead to an improved understanding of how this regulation 
is controlled in health and disease. This is of particular importance when using P2X7 
agonists and antagonists in functional studies, where escape of splice variant activation 
or de-activation may occur. This was considered as I moved forward into vascular 
functional studies in ANGII DOCA salt mice. 
 
6.4 The role of P2X7 in macrovascular function 
Previous studies performed by our lab group showed that use of an AstraZeneca 
compound AZ11657312 as a P2X7 antagonist in rats with ANGII induced 
hypertension led to reduced renal injury (Menzies et al. 2017). However, we were 
unable to reproduce the in vivo effects of AZ11657312 compound seen in our previous 
study in ANGII rats. However, this is not a robust data set: the combination of DOCA-
salt and ANGII made animals unstable under anaesthetic and this resulted in ~50% 
failure rate for this experimental series. Before developing in vivo studies further, I 
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decided to test the effect of AZ11657312 on a murine bone marrow derived 
macrophage (BMDM) population, using the well described P2X7 inhibitor, A438079 
and measuring IL1β as an output of P2X7 activity. This bioassay showed that AZ 
showed an approximate 4-fold drop in P2X7 inhibition compared to A438079. The 
reasons for this are currently unexplored but it is possible that this is yet another 
outcome of the complexity of splice variant isoforms of P2X7. Due to this finding, 
A438079 was carried through to functional studies via myography. 
 
Aortas from Sham and ANGII DOCA salt mice were subject to BzATP 
vasoconstriction in the presence and absence of P2X7 inhibitor A438079; this 
experiment was approached with the hypothesis that ANGII DOCA salt vessels would 
have an increased vasoconstrictor response to P2X7 agonist BzATP, which would be 
dampened by the addition of P2X7 inhibitor A438079. However, there was no 
significant difference in BzATP response between Sham and ANGII DOCA salt 
mouse aortas. This response was unchanged in Sham aortas upon antagonising P2X7 
but was significantly amplified in ANGII DOCA salt aortas. This study was at first 
underpowered, so was repeated with a larger cohort with the same results. 
 
Although P2X7 was upregulated in ANGII DOCA salt mouse kidneys compared to 
sham mouse kidneys, qPCR analysis of p2xr7 showed a decreased expression in 
ANGII DOCA salt aortas, compared to those from Sham animals. This did not 
translate to a difference in BzATP response between these two groups and does not 
account for the increase of vascular constriction of ANGII DOCA salt aortas upon 
treatment with P2X7 inhibitor A438079. However, if different isoforms of P2X7 are 
playing different roles in different tissues, under different pathophysiological 
conditions, it’s possible that the P2X7 isoform profile for ANGII DOCA salt mice is 
different to that in Sham mice. The isoforms within these profiles may well have 
different vasoactive properties. More P2X7 isoform-specific investigation would be 





A more likely explanation for the observations made is the close interplay between 
P2X receptors P2X7 and P2X1. P2X1 is well described as a dominant mediator of 
vasoconstriction in smooth muscle cells, playing a large role in autoregulation in the 
kidney (Inscho et al. 2004). I did measure P2X1 expression through IF studies and WB 
and saw no increase in P2X1 in the ANGII DOCA salt model. Interestingly, at high 
enough concentrations, BzATP can activate P2X1 as well as P2X7, whereas A438079 
is highly specific to P2X7 only. This may explain why no difference was seen in 
BzATP response between sham and ANGII DOCA salt vessels – because BzATP was 
also targeting P2X1, which overrode any differences that might have been seen in 
P2X7. This may well also explain why ANGII DOCA salt aortas responded more 
strongly to BzATP in the presence of a P2X7 inhibitor in ANGII DOCA salt mice – 
blocking P2X7 may result in the overload of P2X1 receptors with BzATP, leading to 
an increased vasoconstrictive response. This effect was, however, only observed an 
ANGII DOCA salt animals, not sham, suggesting that P2X1 is affected by the 
administration of ANGII and/or DOCA salt. In support of my concept; it has 
previously been shown that ANGII administration in rats leads to altered signal 
transduction in P2X1 positive cells, which contributes to the dysfunctional renal 
autoregulation observed in these animals (Zhao et al. 2005). The only way to clearly 
interpret the role of P2X7 in this study would be to incorporate the use of a P2X1 
antagonist, such as NF449, to be able to attribute the changes observed (if any) to P2X7 
alone. 
6.5 Conclusion 
The primary aim of this body of work was to contribute to the growing investigation 
into P2X7 antagonists as renal therapeutic targets. Preclinical models are very 
supportive of this potential (Taylor et al. 2009; Arulkumaram et al. 2011; Menzies et 
al. 2015; Menzies et al. 2017). 
 
My data highlights the complexity and challenge of targeting P2X7 as a renal 
therapeutic. The role of P2X7 in the renal vasculature in still not entirely clear, 
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particularly within models of CKD, and the mechanistic biology of this is not well 
understood. The kidney is a complex organ, composed of many different cell types, it 
could be that P2X7 is playing very contrasting roles in a very tissue specific manner. 
Not only this, but it is evident that P2X7 splice variation cannot be overlooked, with 
splice variants exhibiting different expressions in different tissues and different disease 
models, to the extent that P2X7 antagonists are affected. Without a stronger 
understanding of this splice variation effect, we cannot be sure of the efficacy of P2X7 
antagonists in preclinical and clinical trials. Much discovery biology required to 
provide a mechanistic understanding of this and of the role of P2X7 in specific cell 
types – from immune cells, to pericytes, to endothelial.  
6.6 Summary of further work 
• Build on the expression profile of p2x7r splice variants in the mouse kidney – an extensive 
PCR study is required in order to fully understand what p2x7r splice variants are present 
in different renal cells in the murine kidney under both physiological and 
pathophysiological model. This would allow us to start unpicking the potential different 
roles of P2X7 isoforms. 
• Co-localise P2X7 in the mouse kidney to specific cell markers, particularly PDGFRβ and 
collagen. This would elucidate the potential for a role of P2X7 in pericytes or other 
PDGFRβ expressing cells and the role of P2X7 in perivascular fibrosis. This could be done 
through building on the immunofluorescence studies outlined in this thesis. 
• Further investigation of the role of P2X7 in the microvasculature. This could be done by 
using P2X1 antagonists alongside P2X7 antagonists to eliminate potential of P2X1 
agonism whilst activating P2X7 by BzATP. These studies should also be carried out in 
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